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Although antiretroviral therapy (ART) suppresses viral replication to clinically 
undetectable levels, HIV-1 persists in CD4+ T cells in a latent form not targeted by the 
immune system or ART (Chun et al., 1997b; Finzi et al., 1997; Ruelas and Greene, 2013; 
Siliciano et al., 2003; Wong et al., 1997a). This latent reservoir is a major barrier to cure. 
Many individuals initiate ART during chronic infection, and in this setting, most proviruses 
are defective (Ho et al., 2013a). However, the dynamics of the accumulation and persistence 
of defective proviruses during acute HIV-1 infection are largely unknown. Here we show that 
defective proviruses accumulate rapidly within the first few weeks of infection to make up 
over 93% of all proviruses, regardless of how early ART is initiated. Using an unbiased 
method to amplify near full-length proviral genomes from HIV-1 infected adults treated at 
different stages of infection, we demonstrate that early ART initiation limits the size of the 
reservoir but does not profoundly impact the proviral landscape. This analysis allows us to 
revise our understanding of the composition of proviral populations and estimate the true 
reservoir size in individuals treated early vs. late in infection. Additionally, we demonstrate 
that common assays for measuring the reservoir significantly overestimate or underestimate 
the size of the latent reservoir and no assay we tested correlates with the number of intact 
proviruses. Using our analysis of full-genome sequences, we identify regions and features of 
the HIV-1 genome that, when interrogated simultaneously, specifically distinguish intact 
HIV from defective genomes. We describe here a novel intact proviral DNA assay (IPDA) 
using multiplex droplet digital PCR that allows us to accurately quantify the number of intact 
proviruses, which are likely the closest estimate to the true size of the latent reservoir. In 
preliminary results from matched patient samples, the IPDA strongly correlates with full-
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genome sequencing results. Many defective proviruses contain defects that likely preclude 
elimination by eradication strategies and could obscure the measurement of real changes in 
the rarer intact proviruses. By eliminating 90-95% of all defective proviruses and measuring 
primarily intact proviruses, we anticipate the IDPA will better assess the impact of 
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When HIV-1 was first discovered in the United States in the early 1980’s, an HIV-
1/AIDS diagnosis was a death sentence. In 1987, the first antiretroviral drug to combat the 
virus, 3'-azido-2',3'-dideoxythymidine (AZT), was approved by the FDA. Unfortunately, 
AZT had a significant amount of toxicity (Yarchoan and Broder, 1987) and patients 
frequently developed resistance to single drug antiretroviral regimens. It was only after 
combination therapy that targeted multiple stages of the viral life cycle was introduced in 
1995-1996 that patient outcomes greatly improved (Gulick et al., 1997; Hammer et al., 
1997). Instead of a death sentence, HIV-1 became a manageable but chronic disease, 
requiring daily medication to keep the virus at bay.  
When combination therapy was introduced, it was predicted that patients could be 
cured of HIV-1 after 2 to 3 years on treatment based on the decay rate of the virus in the 
blood of infected individuals (Perelson et al., 1997). However, our lab along with two other 
groups proposed that a dormant or latent state of HIV-1 may exist in the memory CD4+ T 
cells of infected patients that could allow the virus to survive, even in individuals on 
suppressive combination therapy (Chun et al., 1997b; Finzi et al., 1997; 1999). In 1997, our 
lab was able to induce and measure latent virus in the resting CD4+ T cells of patients who 
were fully suppressed on combination ART using an assay called the viral outgrowth assay 
(VOA). This discovery of residual virus that persisted despite effective treatment eliminated 
the hope of curing HIV-1 with antiretroviral therapy alone and necessitated that HIV-1 
infected individuals remain on antiretroviral therapy for life.  
Since that time, we have learned significantly more about this latent reservoir of 
virus. We know that this reservoir of virus is extremely stable with a half-life of 44 months 
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and would take the lifetime of an infected individual to fully decay (Siliciano et al., 2003). 
Additionally, work conducted by Ya-chi Ho in the Siliciano lab recently discovered that the 
majority of viral genomes are actually defective and only a small number can produce 
replication-competent virus	(Ho et al., 2013a). More importantly, her work highlighted that 
the gold standard quantitative viral outgrowth assay (QVOA), which measures viral genomes 
that can produce virions, significantly underestimated the size of the latent reservoir. Thus, it 
could be even more difficult to cure patients than we originally thought	(Ho et al., 2013a).   
My research has expanded the scope of Ya-chi Ho’s original findings, which only 
examined patients treated late in infection, to patients treated early in HIV-1 infection. My 
work has also focused on performing a more comprehensive characterization of the proviral 
landscape in patients as well as developing a more accurate assay to measure the true size of 
the latent reservoir in HIV-1 infected individuals. I believe that the work described in this 
dissertation has contributed to our understanding of what kinds of proviruses are present in 
patients and determined how early defective proviruses begin to accumulate in the resting 
CD4+ cells of patients. These results have broad implications to our assessment and 
understanding of HIV-1 cure strategies.  Finally, we have designed and developed an assay 
that we hope will be a valuable research tool, both in evaluating latency reversal agents in the 
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Chapter 1. Measuring the latent reservoir: An overview of current 
assays 
 
The work presented in this chapter was published in Trends in Microbiology in April 
2015, volume 23(4):192-203.  
1.1 The establishment of HIV-1 latency 
HIV-1 currently infects more than 34 million people worldwide, with over 1.1 
million people infected in the United States alone. Although highly active antiretroviral 
therapy (HAART) is effective in suppressing HIV-1 replication by blocking various 
stages of the viral life cycle, it is not a curative treatment due to the existence of a latent 
viral reservoir in resting memory CD4+ T cells (Chun et al., 1997a; Finzi et al., 1997; 
1999; Wong et al., 1997b). In addition, the latent reservoir (LR) is extremely stable and 
has a long half-life of 44 months, requiring an HIV-1-infected patient to be on HAART 
for the rest of his or her life (Siliciano et al., 2003). The LR is thought to be established 
when HIV-1 infects activated CD4+ helper T cells that are returning to a memory state, 
the result of a normal physiological process occurring after a CD4+ T cell has 
encountered its cognate antigen (Siliciano and Greene, 2011). Since resting memory 
CD4+ T cells are nonpermissive for viral gene expression, the viral genome persists in a 
DNA form as an integrated provirus that is not actively transcribed and resides in cells 
that are not targeted by the host immune system (Ruelas and Greene, 2013). These resting 
memory CD4+ T cells serve as the main LR of HIV-1 and are a major barrier to 
eradication of HIV-1 (Josefsson et al., 2013; Katlama et al., 2013). 
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1.2 Measurement and composition of the latent reservoir 
The LR was first measured and characterized in the late 1990’s using a culture 
technique called the viral outgrowth assay (VOA), which is still considered the current 
gold standard for measuring the number of proviruses in latently infected cells. (Finzi et 
al., 1997; 1999; Siliciano and Siliciano, 2005). The VOA makes use of 
phytohemagglutinin (PHA), a strong global T cell mitogen, which induces release and 
replication of HIV-1 from latently infected cells after one round of maximal activation. 
Since the development of the VOA, other assays such as PCR-based approaches, which 
measure total HIV-1 proviral DNA, have been developed as a simpler method to measure 
the LR (O'Doherty et al., 2002; Rouzioux et al., 2013; Strain et al., 2013). Although both 
culture and PCR-based methods are commonly used, there is little correlation between 
the two. According to initial VOA studies, approximately 1/106 resting CD4+ T cells 
were thought to contain replication-competent virus, but recent studies using PCR-based 
assays show that 300/106 resting CD4+ T cells contain HIV-1 proviral DNA (Eriksson et 
al., 2013).  
These measurement discrepancies are attributed to the heterogeneous population 
of proviruses in the LR. This population of proviruses can be divided into two main 
types: those capable of outgrowth following one round of T cell activation and those that 
don’t replicate, or are noninduced, after one round of T cell activation (Figure 1.1). The 
VOA measures only the former population, whereas PCR-based approaches detect both 
kinds of proviruses, thus partially explaining the lack of correlation between the two 
assays. Interestingly, most noninduced proviruses are defective (Ho et al., 2013a), the 
majority of which contain large internal deletions, which arise by copy choice 
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recombination between two parental viral RNA strands during reverse transcription (Ho 
et al., 2013a; Sanchez et al., 1997; Simon-Loriere and Holmes, 2011). Other defective 
proviruses contain inactivating G to A nucleotide hypermutations by APOBEC3G, a 
cytidine deaminase of the host innate immune defense system (Kieffer et al., 2005; 
Stopak et al., 2003; Yu et al., 2004). APOBEC3G is packaged into budding HIV-1 
virions and after viral infection of a new cell it causes cytidine to uracil deamination on 
the HIV-1 minus strand during reverse transcription, resulting in stop codons in most 
open reading frames. These two types of proviruses are nonfunctional and will not 
produce infectious virus in the VOA. In addition, a small percentage of proviruses that 
are noninduced following a single round of T cell activation have genetically intact 
genomes and have been shown to be replication-competent (Ho et al., 2013a). These 
proviruses are termed intact, noninduced replication-competent proviruses. In order to 
achieve a functional HIV-1 cure, all of the induced as well as intact, noninduced 
replication-competent proviruses must be purged from the LR, since these are the 
proviruses capable of propagating the infection.  
1.3 Accurately measuring changes in the size of latent reservoir 
Currently, the most commonly studied strategy to eliminate the latent reservoir is 
to reverse latency by the shock and kill method (Archin and Margolis, 2014; Deeks, 
2012; Margolis, 2014). The rationale is to “shock” and force HIV-1 out of the reservoir 
by inducing expression of the integrated viral genome. The virus within these cells will 
subsequently undergo RNA synthesis and viral proteins will be translated and expressed. 
The released virus particles would cause killing of the infected T cells by cytopathic 
effects or clearance by the immune system. Histone deacetylase inhibitors (HDACIs) 
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have been shown to be the most effective in reversing HIV-1 latency to date (Archin et 
al., 2012a; 2014; Shirakawa et al., 2013; Ylisastigui et al., 2004), but recent studies have 
shown a discrepancy between the effects of latency reversing agents (LRA) tested on in 
vitro HIV-1 model cell systems and ex vivo primary cells from HIV-1 infected patients 
(Bullen et al., 2014), highlighting a priority in the field to find consistently effective LRA 
candidates that will reduce the size of the latent reservoir in patients. Furthermore, in 
order to determine if these LRAs are effective, it is equally important to develop 
techniques that accurately measure changes in the latent reservoir size.   
Significant progress has been made in developing culture and PCR assays since 
the initial discovery of the latent reservoir of HIV-1 in the 1990’s. However, a detailed 
comparison of all the current assays has shown no precise correlation between the 
measurements made using the VOA or PCR assays (Eriksson et al., 2013). Since 
measuring the latent reservoir differs depending on what assay is used, it is urgent to 
develop a high-throughput and reliable assay that is sensitive and can accurately measure 
the true size of the latent reservoir. This is especially important in determining the 
efficacy of pharmacological agents used in current or future clinical trials to decrease or 
eliminate the latent reservoir and to reliably conclude if a functional or sterile cure has 
been achieved in HIV-1-infected patients undergoing eradication treatments.  
1.4 Culture-based assays to measure the latent reservoir 
The LR was initially defined and measured using the viral outgrowth assay 
(VOA), a culture-based assay that is still considered the gold standard to measure 
outgrowth of HIV-1 from latently infected resting T cells (Finzi et al., 1997; 1999). To 
set up a VOA, resting CD4+ T cells are isolated from a patient on HAART and plated in 
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fivefold serial dilution. Phytohemagglutinin (PHA), a lectin, is combined with irradiated 
allogeneic PBMCs, called feeders and added to resting CD4+ T cells to induce global T 
cell activation. The feeders are added to ensure successful activation since they contain 
macrophage and dendritic cells, which act as antigen-presenting cells (Siliciano and 
Siliciano, 2005). Initially, CD4+ lymphoblasts from HIV-1-negative donors were used to 
amplify released virus from the patient cells to detectable levels, but this process can be 
simplified by using a self-replicating cell line called MOLT-4/CCR5, which expresses 
high levels of CD4 and CXCR4 and can be stably transfected with CCR5, a co-receptor 
for HIV-1 viral entry (Laird et al., 2013). The patient cells are co-cultured with 
lymphoblasts or MOLT4 cells for two to three weeks and then are analyzed for viral 
outgrowth using a p24 ELISA assay. Alternatively, a highly sensitive RT-PCR can detect 
viral outgrowth in as early as seven days after activation (Laird et al., 2013). Recent work 
used a modified culture assay to allow for <1 virus producing cell per well for better 
quantification of HIV-1 with no need for amplification of the virus before PCR 
measurement. In addition, it allows for the detection of any provirus that goes on produce 
unspliced RNA after activation, even if mature virions are not produced (Cillo et al., 
2014a).  Although the VOA has a number of advantages including the ability to isolate 
and culture latently infected cells from patients and to detect the outgrowth of replication-
competent virus (Finzi et al., 1997; 1999), recent studies have shown that the VOA 
underestimates the true size of the LR and that the LR is actually larger than the 1 
replication-competent provirus per 106 resting CD4+ T cells measured by the VOA (Ho 
et al., 2013a). While the VOA can detect proviruses that are induced after one round of 
maximal T cell activation, it cannot detect intact, noninduced replication-competent 
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proviruses, which may pose as a barrier to curing HIV-1. Additionally, the VOA uses 
large volumes of blood (120-180mL), is expensive and requires 3 weeks of culture in a 
BSL3 laboratory. These shortcomings need to be kept in mind when using the VOA to 
measure LR size in patients. 
1.5 PCR-based assays to measure the latent reservoir 
Complementary approaches to the VOA are PCR-based assays to measure the LR. 
These methods provide a quicker and easier approach for studying the LR and can be 
applied to a variety of immune cell types. The most common PCR method for measuring 
the LR is a quantitative PCR (qPCR) using either resting CD4 T cells (McBride et al., 
2013), unfractionated peripheral blood mononuclear cells  (PBMCs), (Besson et al., 
2012; Gandhi et al., 2012; Hatano et al., 2009; Rouzioux et al., 2013; Zhu et al., 2011) or 
bulk CD4+ T cells (Chun et al., 2011; Markowitz et al., 2014). All methods involve 
isolating the desired cell populations from patient blood and subsequently extracting the 
DNA. A qPCR using primers in conserved regions of the HIV-1 genome is carried out on 
the DNA extracts. The number of infected cells is calculated using a standard curve of 
known amounts of DNA from a plasmid standard such as pNL4-3. RNase P, a 
ribonuclease that is present in two copies per diploid genome, is frequently used to 
determine the total number of cells in the sample. The standard curve and total cell 
number estimates the frequency of cells that harbor HIV-1 DNA. These methods have 
also been adapted to measure proviral DNA in the gut associated lymphoid tissue 
(GALT) (Chun et al., 2008; Yukl et al., 2010), a region thought to possibly be another 
reservoir of HIV-1 latency, as well as in CD4+ T cells in the bone marrow (Durand et al., 
2012). Other PCR methods take advantage of the highly precise measurements of digital 
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droplet PCR to measure HIV-1 DNA in CD4 T cells (Eriksson et al., 2013; Strain et al., 
2013) as well as PBMCs (Eriksson et al., 2013; Tebas et al., 2014). The DNA is extracted 
in the same manner as with qPCR, however, the sample is divided into thousands of 
droplets, allowing for single template amplification and detection. This allows for precise 
and absolute quantification of HIV-1 DNA rather than relative quantification derived 
from a standard curve, as with qPCR.  
In measuring the LR, it is important to detect only integrated proviruses, not 
extra-chromosomal HIV-1 DNA resulting from residual viremia or viral blips. Multiple 
methods have been developed to measure only integrated HIV-1 proviral DNA. The most 
common method is Alu-PCR which can be applied to either CD4+ T cells or PBMCs 
(Brady et al., 2013; Liszewski et al., 2009; Mexas et al., 2012; O'Doherty et al., 2002). 
Alu-PCR amplifies only integrated HIV-1 genomes by using one primer targeted for Alu 
elements, which are found in high copy numbers in the human genome, and a second 
primer located in the HIV-1 gag gene. Proviruses integrated in proximity to Alu elements 
are detected while nonintegrated viruses are excluded. A standard curve is used to 
account for proviral genomes that are too far from an Alu sequence to be detected. 
Alternative methods for measuring integrated proviruses include linker ligation PCR 
(Vandegraaff et al., 2001) and inverse PCR (Chun et al., 1997a). When Alu-PCR was 
compared side by side to methods detecting all proviral DNA in patients on suppressive 
HAART, there was a strong correlation between the two methods indicating the majority 
of proviral DNA in HAART patients is integrated (Eriksson et al., 2013). Although 
unintegrated proviruses are not considered to be part of the LR and are typically found in 
low levels in patients on HAART (Besson et al., 2012; Gandhi et al., 2012; Mexas et al., 
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2012), unintegrated forms such as 2-long terminal repeat (LTR) circles are commonly 
used as a measure of recent infection or ongoing replication. A number of assays have 
been developed to study unintegrated forms of HIV-1 including a digital droplet PCR 
assay on resting CD4+ T cells and PBMCs (Eriksson et al., 2013), as well as a  qPCR 
assay on PBMCs (Butler et al., 2001; Buzón et al., 2010; Zhu et al., 2011). These assays 
use primers flanking the 2-LTR circle junction, a region unique to 2-LTR circles and not 
found in integrated proviruses to amplify only unintegrated virus.  
PCR-based methods have also been instrumental in shaping our understanding of 
the LR. While the culture-based VOA is expensive, labor intensive, and requires a large 
input of blood, PCR assays provide a much quicker, cheaper, and easier alternative. 
However, when compared to the VOA, PCR assays give infected cell frequencies that are 
at least two logs higher than those detected by the VOA (Eriksson et al., 2013). While the 
VOA underestimates the true size of the LR since one round of activation doesn’t release 
all replication-competent proviruses, PCR assays overestimate the latent reservoir 
because they cannot discriminate between defective and replication-competent 
proviruses. Both types of assays provide different measures of the LR and highlight the 
importance of using multiple measurements to give an accurate picture of the LR. 
1.6 Measuring Residual Viremia 
While HAART is effective in suppressing viremia to below the clinical limit of 
detection of 50 copies/mL, replication-competent virus can still be detected at low levels 
in the plasma, indicating persistent residual viremia despite the presence of HAART 
(Sahu et al., 2010). To measure residual viremia, the highly sensitive single-copy assay 
(SCA) was developed and can detect down to one copy of HIV-1 RNA per mL of plasma 
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(Dahl et al., 2013; Palmer, 2013; Palmer et al., 2003). The SCA is a two-step RT-PCR 
that uses primers against a conserved region of gag in the HIV-1 genome. Although the 
SCA is a useful tool for measuring viral persistence in the plasma, it doesn’t measure the 
size of the LR within resting CD4+ T cells, thus it is not the best measure to quantify 
changes in the LR on someone receiving eradication treatment. The SCA combined with 
both culture and PCR-based assays may provide an effective method to quantify the LR 
in a patient undergoing suppressive HAART.  
1.7 Treatment interruption and time to rebound 
Initially, it was thought that only a few years of HAART treatment would be 
necessary to cure a patient. However, the discovery of the LR and its long-term stability 
has rejected this notion and patients must remain on HAART their entire lives. There is a 
growing trend in HIV-1 eradication studies and among HIV-1 patients who have 
undergone bone marrow transplantations (Henrich et al., 2013; Hütter et al., 2009; Yukl 
et al., 2013) to stop HAART treatment and determine LR size by the time it takes for 
viral rebound to occur. This was done in the case of the two HIV-1 positive “Boston 
patients”, who had undetectable levels of HIV-1 DNA after undergoing allogeneic stem 
cell transplantations for cancer treatment (Henrich et al., 2013). However, these patients 
had a rebound of viremia months after stopping HAART treatment	 (Henrich et al., 2014). 
Although taking a patient off of HAART is ultimately the only way to determine if a 
patient is cured, there are precautions and ethical issues to consider when using “time to 
rebound” as a measurement of LR size. Studies have shown that drug resistance can 
occur as a result of patient non-adherence to medication or as a result of treatment 
interruption (Arnedo-Valero et al., 2005; Luebbert et al., 2012). Additional difficulties 
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with this approach include the uncertainty of if or when rebound will occur. If the LR is 
reduced significantly in size but not entirely eliminated, it could take months or years to 
determine whether or not the patient was actually cured.  
1.8 Current Measurements in Eradication Clinical Trials 
Since latency-reversing agents (LRAs) seek to reactivate HIV-1 by inducing 
transcription of the latent provirus into RNA, it is important to have methods to detect 
changes in HIV-1 RNA production. Thus, in addition to the VOA, qPCR-based methods 
have been developed for measuring HIV-1 RNA production in PBMCs (Hatano et al., 
2009; Yukl et al., 2010), resting CD4+ T cells (Archin et al., 2012a), and in the GALT  
(Eriksson et al., 2013; Yukl et al., 2010) as well as measuring HIV-1 mRNA in resting 
CD4+ T cells (Bullen et al., 2014). Digital droplet PCR has also been to quantify HIV-1 
RNA (Jones et al., 2014). In addition to determining whether or not a LRA has been 
effective in “shocking” the virus to produce RNA, it is also important to determine 
whether or not the infected cells have been “killed” and eliminated from the reservoir. In 
order to do this, an accurate measure of the LR before and after treatment(s) is necessary. 
Table 1.1 summarizes the different assays used in measuring the LR. Current eradication 
trials involve the administration of monoclonal antibodies, cytokines, HDAC inhibitors 
(Archin et al., 2012a; Rasmussen et al., 2014b), gene therapies (Tebas et al., 2014), and 
intensification treatments (Puertas et al., 2014). Most current and future trials will 
measure LRA efficacy by either outgrowth of virus with the VOA, cell-associated RNA, 
plasma RNA, and total and integrated HIV-1 DNA, or a combination of multiple 
measures as is shown in Table 1.2. The outcomes of these trials will vary since 
measuring the latent reservoir differs depending on what assay is used. 
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1.9 Discussion 
Following the discovery of the LR in resting memory T cells and its long-term 
stability, it has become an urgent task to identify ways to eliminate this major barrier to 
eradication. Currently, the predominant strategy to eliminate the LR is the “shock and 
kill” method which aims to “shock” HIV-1 out of the LR by inducing HIV-1 gene 
expression and “kill” infected host cells by way of cytotoxic and immune clearance. It 
has also become a high priority in the field to develop better ways to measure the LR 
(International AIDS Society Scientific Working Group on HIV Cure et al., 2012), since 
current eradication trials lack a universal measure to assess whether or not a decrease in 
the LR has been achieved. Although many assays have been developed to quantify the 
LR, there is little correlation between the methods (Eriksson et al., 2013). The only 
correlation that has been observed between culture and PCR assays is between an Alu 
PCR specific for integrated DNA in PBMCs and the VOA. Despite a correlation between 
methods, the Alu PCR still gave infected cell frequencies at least two logs higher than 
those detected by the VOA (Eriksson et al., 2013).  
In addition to a lack of correlation between methods, there are also drawbacks to 
both PCR-based and culture assays that need to be considered when using them to 
measure the LR or evaluate eradication therapies. The VOA is still considered the gold 
standard for measuring the LR, however it underestimates the true size of the LR since it 
cannot detect all latently infected cells that may pose a barrier to an HIV-1 cure (Ho et 
al., 2013a). Underestimating the size of the LR may cause a patient to appear “cured”, 
however the patient may still contain latent HIV-1, and if taken off of HAART treatment, 
viral rebound may occur. PCR-based assays are also commonly used to quantify proviral 
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DNA, but they cannot distinguish between replication-competent and defective 
proviruses. An additional concern in using PCR-based assays arises from the fact that 
many defective proviruses such as those containing lethal hypermutations or large 
deletions would be unable to produce viral proteins even if latency was successfully 
reversed. Elimination of infected cells is likely dependent upon viral protein production, 
thus cells containing defective proviruses may not be eliminated even by successful 
strategies. In this situation, large numbers of defective viruses could potentially mask 
successful clearance of latently infected cells resulting from latency reversal therapy. 
Using PCR assays to measure the efficacy of eradiation agents could possibly lead to the 
rejection of a successful strategy. Since PCR-based measurements detect defective 
proviruses as well, it would also be impossible to know when the true latent reservoir has 
been successfully cleared and when patients can safely be removed from therapy.   
Since there are no current assays available that can accurately detect whether or 
not a patient is “cured” or whether or not a decrease in the LR has been achieved, 
treatment interruption of HAART in patients is also used to measure reduction in 
reservoir size in eradication trials. Although treatment interruption is the only definitive 
way to know whether or not a functional cure has been achieved, there are many concerns 
with this approach. In 2006, the SMART study compared prolonged HAART treatment, 
which is now considered the standard treatment of care today, to episodic treatment with 
antiretrovirals followed by treatment interruption until CD4+ T cell levels dropped below 
a predetermined threshold (Strategies for Management of Antiretroviral Therapy 
(SMART) Study Group et al., 2006). The patients with treatment interruption 
experienced higher levels of morbidity, opportunistic diseases, and malignancies 
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compared to those on continued treatment (Pace and Frater, 2014; Routy et al., 2012; 
Silverberg et al., 2007; Strategies for Management of Antiretroviral Therapy (SMART) 
Study Group et al., 2006). Considering the precautions and ethical considerations in 
removing patients from treatment, it remains necessary to have assays that can measure 
the effects of therapeutic interventions on reservoir size without the need for treatment 
interruption. 
The main goal in eradication clinical trials is to identify agents that cause a 
decrease in the LR in HIV-1-infected patients. The current assays available do not 
correlate well with one another and none measure the true size of the LR (Figure 1.2), 
which prevent accurate identification of successful agents proposed to eliminate the LR 
as well as comparisons between different eradication trials. In the absence of a universal 
method of measurement, many clinical trials are using a combination of culture and PCR 
methods to identify and measure changes in the LR as shown in Table 1.2. However, the 
conclusions drawn from these trials will vary depending on the specific measurements 
used. In order to reliably conclude if an agent is effective or if a cure has been achieved, 
an assay is needed that can measure latently infected cells that have the potential to 
produce replication-competent virus in vivo, since these are the only proviruses that may 
pose a threat to eradication. A high throughput, sensitive, and well-validated assay would 




1.10 Tables: Chapter 1  
Table 1.1 Comparison of assays for measuring the HIV-1 latent reservoir 
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virus induced by single 
round of T cell activation. 
Can in principle detect 
linear unintegrated HIV-1 
DNA in recently infected 
cells. For this reason, 
the VOA is only useful 
as a measure of the LR 
in patients who have had 
prolonged suppression 









1- and 2-LTR 
circles 
p24 ELISA or 
RT-PCR 
Allows for quantification 
of induced replication-
competent proviruses 
without detection of 
defective proviruses 
 
-Expensive and requires a large 
blood volume (120-180 mL)  
 
-Time consuming (requires 2-3 
weeks tissue culture in a BSL3 
laboratory) 
 
-Limited dynamic range 
because levels in most patient 
on ART are close to the limit of 
detection with the standard 
sample volume (180 mL blood) 
 
-Does not detect all proviruses 








Fraction of proviruses 
that can be induced to 
make either cell 
associated unspliced or 
multiply spliced HIV-1 
RNA or full length HIV-1 
mRNA released into the 
culture supernatant 







RNA after a 
single round of 
activation 
(INPs) 




-Less culture time is 
required than the VOA 
 
-Requires 2-7 days of culture in 
a BSL3 laboratory 
 
-Does not detect all proviruses 
that potentially pose a barrier to 
a cure  
 




1 DNA  
Total proviral DNA 
including replication-
competent proviruses, 
defective proviruses, and 







qPCR Easy, quick, and does 
not require any 
extended culture time 
in a BSL3 laboratory 
 
 
-Detects many proviruses that 
do not pose a barrier to an HIV-
1 cure 
 
-Provides quantitation relative 
to a standard curve, but not an 
absolute value. Different qPCR 






Total proviral DNA 
including replication-
competent proviruses, 
defective proviruses, and 





regions   
 
 
ddPCR Highly precise; 
provides an absolute 
quantitation rather than 
a relative one 
Detects many proviruses that 




Alu PCR for 
Integrated 
HIV-1 DNA 







HIV-1 DNA  
 
qPCR Useful in measuring 
integrated proviruses in 
untreated patients, in 
which large amounts of 
unintegrated DNA can 
confound total proviral 
DNA measurements 
Does not detect proviruses that 
are too far from an Alu 
sequence to be amplified, but 
uses a correction factor to 
account for these; also detects 




2-LTR circles Integrated 
proviral DNA 
qPCR Used to measure 
ongoing replication 
based on the 
controversial 
assumption that the 
circles are labile 
Does not detect integrated 
provirus, which is the only form 






2-LTR circles Integrated 
proviral DNA 
ddPCR Highly precise; 
provides an absolute 
quantitation rather than 
a relative one; used to 
measure ongoing 
replication  
Does not detect integrated 
provirus, which is the only form 




Residual viremia Proviral DNA 
within cells or 
compartments 
RT-PCR Valuable as a measure 
of ongoing virus 
production in the 
setting of ART 
-Time consuming and does not 
directly measure the LR as the 
residual viremia may also 
originate from other reservoirs.  
 
-Limited dynamic range 
because levels in most patients 
on ART are close to the limit of 
detection with the standard 
sample volume (8 ml plasma). 
[77-81] 
	 15	












University of California, 




Change in RNA in total CD4s and 





University of California, 
San Francisco/Monash 
University/American 






Cell-associated RNA in total and 
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AIDS Clinical Trials 
Group/National 
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December 2015 




Modified T cells 
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IL-2 
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frequency of latent replication-
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in PBMCs and total CD4s, 
defective DNA sequences and 




University of North 
Carolina at Chapel 
Hill/Argos 
Therapeutics/U.S. 




and HIV strain 
Plasma RNA by SCA and VOA January 2016 
Vorinostat NCT01365065 
 
Bayside/Merck HDAC inhibitor Plasma RNA by SCA and 
unspliced RNA in CD4s 
March 2016 




Plasma RNA by SCA, total DNA, 
2LTR circle DNA, cell-associated 









Cytokine Alu-HIV gag PCR to detect change 








(TLR)-3 agonist  
Cell-associated RNA, plasma RNA 
by SCA, and proviral DNA 
June 2017 
New Era Study NCT00908544 
 









Cell-associated proviral DNA in 
PBMCs and total CD4s, plasma 
RNA by SCA 
November 2019 
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1.11 Figures: Chapter 1  
Figure 1.1 Profile of different types of HIV-1 proviruses in resting CD4+ T cells 
 
The major types of proviruses are shown, including those that pose a barrier to an HIV-1 
cure and those that do not. Following a single round of T cell activation, some proviruses 
are induced to produce virions, which can infect other cells (induced, replication- 
competent proviruses). Proviruses that are not induced to produce replication-competent 
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virions following a single round of T cell activation are termed noninduced proviruses. 
Many of these noninduced proviruses are defective and contain large internal deletions, G 
to A hypermutations, or other inactivating defects. However, some noninduced 
proviruses have fully intact genomes and, on subsequent rounds of cellular activation, can 
produce virions. These proviruses are termed intact, noninduced proviruses (INPs). 
Culture-based assays detect induced replication-competent proviruses only, while PCR-
based assays detect all types of proviruses. Only induced replication-competent 
proviruses and INPs pose a barrier to an HIV-1 cure. 
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Figure 1.2 Venn diagram comparison of proviral populations measured by different 
methods of assessing the latent reservoir (LR) 
 
 Typical or estimated results from various PCR- and culture-based assays are shown 
relative to a prediction of the true LR size. The frequency of infected cells detected by the 
different assays is represented by the area of each circle. PCR-based assays overestimate 
the LR since most of the templates amplified represent defective viruses (Ho et al., 
2013b; Eriksson et al., 2013). Additionally, some proviruses are likely to be deleted in the 
primer binding sites for the PCR, so PCR-based assays are likely to underestimate the 
total number of infected cells. The viral outgrowth assay (VOA) underestimates the LR 
size because not every replication-competent virus is induced by a single round of T cell 
activation (Ho et al., 2013a). Assays involving T cell activation with a viral RNA readout 
give intermediate values but suffer from both of the problems mentioned above: some of 
the viral RNA detected is derived from defective proviruses and not all of the replication-
competent proviruses are induced by a single round of activation  (Cillo et al., 2014b; 
Laird et al., 2013). There is a need for assays that measure only those proviruses that pose 
a threat to an HIV-1 cure.  
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Chapter 2. Defective proviruses rapidly accumulate during acute HIV-1 
infection 
 
The work presented in this chapter was published in Nature Medicine in September 2016, 
volume 22(9):1043-9.  
2.1 Introduction 
HIV-1 establishes infection in CD4+ T cells (Chun et al., 1997b; Finzi et al., 1997; 
1999), generating a latent reservoir with an extremely long half-life (44 months) that 
necessitates life-long treatment (Crooks et al., 2015; Siliciano et al., 2003). Efforts to 
eradicate this reservoir include the “shock-and-kill” approach in which latent proviruses 
are induced so that infected cells can be eliminated (Archin and Margolis, 2014; Deeks, 
2012; Archin et al., 2012a). The latent reservoir was initially defined using a quantitative 
viral outgrowth assay (QVOA) (Crooks et al., 2015; Finzi et al., 1997; Laird et al., 2013; 
Siliciano and Siliciano, 2005). PCR can also detect proviral DNA (Henrich et al., 2012; 
Rouzioux et al., 2013; Strain et al., 2013). However, the QVOA and PCR assays correlate 
poorly (Eriksson et al., 2013). We recently examined discrepancies between the assays by 
sequencing gag+ proviruses from QVOA wells negative for viral outgrowth (Ho et al., 
2013a). Most proviruses were defective, but 12% were intact, and some of these could be 
reactivated following a second round of T cell activation (Ho et al., 2013a). However, 
these studies were limited to individuals who initiated ART late in the course of infection 
and only analyzed gag+ proviruses in cells that had been expanded for weeks in culture 
(Ho et al., 2013a). As immediate ART is now recommended for all infected individuals 
(Günthard et al., 2014), and since the size and perhaps other characteristics of the 
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reservoir differ in individuals treated early versus late in infection (Archin et al., 2012b; 
Deng et al., 2015; Jain et al., 2013), we sought to define the composition of proviral 
populations in individuals treated during acute infection. As cure efforts advance, it is 
essential to understand how defective proviruses accumulate, persist in individuals and 
affect reservoir assay measurements. Therefore, we conducted a proviral analysis in 
unmanipulated samples from HIV-1 infected adults treated at different stages of 
infection.  
2.2 Results 
We developed a novel, unbiased single genome amplification method that 
captures intact and defective proviruses. Since deletions likely occur during minus strand 
synthesis before the second strand transfer event of reverse transcription, primers were 
designed to capture deletions arising during this process (Fig. 2.1a) (Delviks-
Frankenberry et al., 2011; Jetzt et al., 2000; Yu et al., 1998). PCRs were performed at 
limiting dilution to prevent in vitro recombination and competition between short and 
long templates. Following the near full length outer PCR, gag and env inner PCRs were 
used to confirm clonality, and six overlapping inner PCRs were performed on all wells at 
limiting dilution (Fig 2.1b). PCR products were directly sequenced to minimize PCR-
induced error.  
We examined proviral DNA in purified resting CD4+ T cells from ten subjects 
initiating ART during the chronic phase of infection (CP; ART started >180 days after 
infection) (Table 2.1). Analysis was performed on freshly isolated cells to prevent bias 
from in vitro expansion. Strikingly, 98% of proviruses were defective (Fig. 2.2 a,b and 
Fig. 2.3). The most common defects were internal deletions (80%), which varied in size 
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(15 bp to ~8 kb) and in location in the genome. Some proviruses had 3’ deletions 
affecting the env, tat, rev and nef genes. We also identified proviruses with 5’ deletions 
affecting gag and pol and others with very large deletions (>6 kb) encompassing most 
HIV-1 genes (Fig. 2.2 a,b). The 5’ deletions and very large deletions, representing 40% 
of all sequences, were not identified in a previous screen because they contain deletions 
in the gag gene (Ho et al., 2013a). Proviruses with small (15-97bp) deletions at the 
packaging signal and major splice donor site represented 5% of sequences (Fig. 2.2b). 
These proviruses are likely replication-defective due to failure to correctly make spliced 
HIV-1 RNAs or to package genomes into virions (Ho et al., 2013a). Some clones 
contained multiple deletions suggesting multiple template switching events during 
reverse transcription (Fig. 2.2a) and others contained sequence inversions or insertions 
(Fig. 2.2b). For each type of deletion, proviruses with sequence homology at the deletion 
junctions were found (Fig. 2.2c), consistent with template switching during reverse 
transcription (Hwang et al., 2001). In control experiments, plasmids containing reference 
(NL4-3) or patient-derived proviruses were diluted into human genomic DNA and 
amplified by the same procedure with no defects observed (data not shown). 
Additionally, deletions showed nonrandom distribution within the HIV-1 genome with 
distinct hotspots (Fig. 2.4) and we observed identical deletions in independent 
amplifications from the same subject, reflecting clonal expansion of infected cells (see 
below). Taken together, these results indicate that the deletions we observe occurred in 
vivo and do not result from PCR recombination. We also identified 7% of proviruses with 
APOBEC3F/G-induced hypermutation and an additional 8% with both deletions and 
hypermutation, indicating that these processes can occur together during reverse 
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transcription (Fig. 2.2b). Almost all hypermutated proviruses contained mutated start 
codons for the gag, gag-pol and nef ORFs due to the presence of an obligatory position 2 
glycine codon which creates the APOBEC3G consensus site, ATGGGT (Kieffer et al., 
2005; Yu et al., 2004). Additionally, all hypermutated sequences had multiple internal 
stop codons in the larger ORFs (gag, gag-pol, env, nef) and only a small fraction could 
make functional gene products (Fig. 2.5). These defects and common deletions affecting 
key viral ORFs (Fig. 2.2a,b) likely prevent many defective proviruses from being 
eliminated by eradication strategies that depend on viral protein expression. All subjects 
had undetectable viral loads (<50copies/mL) for >8 months prior to sampling and all but 
one had low frequencies of 2LTR circles in cells (< 25 copies/106 resting CD4+ T cells), 
which represented less than 8% of the total number of infected cells (Fig. 2.6). The labile 
nature of linear unintegrated HIV-1 DNA and the low level of 2LTR circles suggest the 
majority of the sequences examined were integrated proviruses (Pierson et al., 2002). Of 
152 near full-length sequences examined, only 3 sequences were intact (2%). These data 
indicate that defective proviruses are much more common than previously shown (Fig. 
2.2b). 
Since the dynamics of proviral accumulation remain unclear, we sought to 
determine how rapidly defective proviruses accumulate. We examined the proviral 
populations in subjects treated during the acute/early phase of infection (AP; ART started 
within 100 days in all subjects and within 60 days in 8 of 9 subjects) (Table 2.1). 
Surprisingly, only 7% of proviruses were intact, even in subjects 2453, 2454, 3693, and 
2443 who initiated ART within the first few weeks of infection (Fig. 2.7a,d and Fig. 2.8). 
Although, the number of individuals subjected to this extensive analysis was small, the 
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results were very consistent between subjects. The remaining proviral sequences 
contained defects similar to those in CP-treated subjects (Fig. 2.7a,d) and there was no 
significant difference in the fraction of intact proviruses compared to CP-treated subjects 
(Fig. 2.9a). AP-treated subjects had a higher fraction of hypermutated sequences (35% 
vs. 14%, P = 0.0036, Fig. 2.9b) and a significantly lower fraction of deleted sequences 
(57% vs. 82%, P = 0.0028, Fig. 2.9c) suggesting that hypermutation is particularly 
important during acute infection, perhaps due to upregulation of APOBEC3G/F by type I 
interferons (Harper et al., 2015; Pillai et al., 2012; Stacey et al., 2009). Interestingly, 
defects are even detectable in a single round of in vitro infection (41% of sequences, Fig. 
2.7b,d). Consistent with this result, we readily detected defective proviruses in 
unfractionated CD4+ T cells from viremic subjects in the chronic phase of infection, 
representing 65% of sequences (Fig. 2.7c,d). In these subjects, the provirus populations 
include both proviruses in newly infected cells and archived proviruses in the reservoir. 
These results indicate that defective proviruses are likely generated during the initial 
rounds of replication after transmission, as defective proviruses are generated at a high 
frequency from the process of reverse transcription (Fig. 2.7b).  Since many of the 
proviruses identified have defects that would preclude high-level expression of viral 
genes, cells carrying these proviruses would likely be less susceptible to elimination 
through viral cytopathic effects or lysis by cytotoxic T lymphocytes. Thus even 
individuals treated very early have large numbers of defective proviruses. Together, these 
results demonstrate that defective proviruses arise commonly, accumulate rapidly within 
two to three weeks after infection, and persist in vivo.  
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Proliferation of cells carrying replication-competent proviruses could be a major 
barrier to eradication (Kearney et al., 2015; Maldarelli et al., 2014; Wagner et al., 2014). 
Integration-site analysis, pioneered by Schröder et al. (Schröder et al., 2002), has 
provided important evidence for proliferation of infected cells in vivo but does not reveal 
whether the proviruses are replication-competent (Cohn et al., 2015; Maldarelli et al., 
2014; Wagner et al., 2014). Our unbiased analysis allowed us to detect expanded cellular 
clones in vivo and evaluate the presence of defects. Among 312 sequences from 9 AP- 
(Fig. 2.10a) and 10 CP-treated subjects (Fig 2.10b), 38 were from expanded cellular 
clones identified as identical sequences arising from independent amplifications. 
Importantly, all contained gross defects that preclude replication (Fig. 2.11a,b). In 
subjects 2529, 2609, CP03, CP05, and CP10, expanded clones represented over 25% of 
all the sequences (Fig. 2.10a,b). Subject 2521 contained an expanded clone representing 
11% of all proviral sequences (Fig. 2.10a, 2.11a) after just 17 months of infection and 8 
months on suppressive ART, indicating expanded clones do not require years to 
accumulate to large proportions. Our results indicate the majority of expanded clones are 
defective. However, considering that <7% of proviruses are intact, rare expanded clones 
may carry replication-competent virus and contribute to HIV-1 persistence, as was seen 
in a recent clinical case study (Kim and Siliciano, 2016; Simonetti et al., 2016). Although 
cells harboring defective proviruses can undergo clonal expansion with minimal 
consequences to the host cells, cells harboring replication-competent viruses could likely 
expand through either activation of the cell but not the provirus (Bosque et al., 2011) or 
possibly proliferation and survival of the cells despite viral gene expression and virion 
production.   
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Our analyses show that the fraction of intact proviruses is much lower than 
originally thought even in individuals treated early. We have previously shown that intact 
proviruses replicate well in vitro when reconstructed (Ho et al., 2013a).  Furthermore, 
when wells that were negative for viral outgrowth in the VOA were reactivated, 
additional replication competent virus was isolated (Ho et al., 2013a). These data taken 
together suggest that some if not all of these intact proviruses are competent for viral 
replication and that the number of intact proviruses is likely the closest estimate to the 
true size of the latent reservoir.  Given these results, we sought to more accurately 
estimate the true reservoir size in AP- and CP- treated individuals, as defined by the 
number of intact proviruses, and compare that result to current assays such as the QVOA 
and DNA PCR. We used a validated droplet digital method for proviral DNA with gag 
primers (Massanella et al., 2015; Strain et al., 2013) (gag+ proviruses) and corrected for 
proviruses deleted in gag (total number of infected cells).  The DNA PCR assay gave 
infected cell frequencies dramatically higher than the frequency of cells with intact 
proviruses (P < 0.0001 for CP-treated; P < 0.0001 for AP-treated subjects). The QVOA 
gave infected cell frequencies that were dramatically lower than the frequency of cells 
with intact proviruses (P < 0.001 for CP-treated; P < 0.01 for AP-treated subjects) (Fig. 
2.12a,b). We found that the QVOA potentially underestimates the latent reservoir by a 
median of 27-fold in CP-treated subjects and 25-fold in AP-treated subjects (Fig. 2.12c). 
However, DNA PCR overestimated the reservoir size by a median of 188-fold in CP-
treated subjects and 13-fold in AP-treated subjects (Fig. 2.12c). Importantly, there was no 
correlation between the number of intact proviruses and either the QVOA or DNA PCR 
results (Fig 2.13a-c). Additionally, the relationships between the QVOA, intact 
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proviruses, and proviral DNA varied greatly from person to person in both CP-(Fig. 
2.12d and Fig. 2.14a) and AP-treated subjects (Fig. 2.12e and Fig. 2.14b). This precludes 
the use of either the QVOA or DNA PCR as a surrogate marker for the number of intact 
proviruses, which is likely the closest estimate of the true size of the latent reservoir.  
2.3 Discussion 
This unbiased screen demonstrates that the fraction of intact proviruses is 
considerably smaller than previously shown and that defects accumulate as early as two 
to three weeks after infection.  Although surprising, the rapid accumulation is consistent 
with the observation that defects can be observed in 40% of proviruses generated in a 
single round in vitro infection (Fig. 2.7d) and the fact that cells harboring defective 
proviruses may be less susceptible to immune clearance or cytopathic effects.  With these 
new data, we were able to revise our estimates of the reservoir size in both CP- and AP-
treated individuals. If all intact proviruses can be induced in vivo, the true size of the 
latent reservoir would be on average 12 infectious proviruses (median of AP-treated) in 
acute/early treated individuals and 37 infectious proviruses (median of CP-treated) per 
million resting CD4+ T cells in chronically treated individuals, with substantial person-to-
person variation. Furthermore, our results change our understanding of the impact of 
early ART on the proviral landscape. While early ART initiation limits the size of the 
latent reservoir, it does not have a profound impact on the composition of proviral 
populations, with the vast majority of proviruses in both CP- and AP-treated adults 
containing defects. Finally, these results have implications for assessing HIV-1 cure 
strategies. Since there is no correlation between the QVOA or DNA PCR and the number 
of intact proviruses, these assays cannot be used to accurately predict the true reservoir 
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size, even in individuals treated early in infection. Indeed any analysis of subgenomic 
regions of proviruses to evaluate viral evolution or reservoir reduction must be 
reconsidered in this context, since the majority of sequences studied will be from 
defective proviruses (Lorenzo-Redondo et al., 2016). Importantly, since the nature of the 
defects described here indicates that many defective proviruses may not be eliminated by 
eradication strategies, defective proviruses could obscure the measurement of real 
changes in the rarer intact proviruses that must be eliminated to achieve a cure.  
2.4 Materials and Methods 
Study subjects 
The Johns Hopkins Institutional Review Board and the UCSF Committee on 
Human Research approved this study. All participants provided written consent prior to 
enrollment. Nineteen HIV-1 infected individuals who met the criteria of suppressive ART 
and undetectable plasma HIV-1 RNA level (< 50 copies per mL) for a minimum of 8 
months were enrolled. Ten of these participants were recruited from the SCOPE and 
OPTIONS cohorts at the University of California, San Francisco. CP-treated subjects are 
defined as subjects starting ART >180 days from the estimated date of infection. AP-
treated subjects started ART < 100 days after the estimated date of infection. Viremic 
subjects were either untreated or had viral loads > 4000 copies/ml on ART. Table 2.1 
details the characteristics of study participants.  
Isolation of resting CD4+ T lymphocytes 
Peripheral blood mononuclear cells (PBMCs) were isolated using density 
centrifugation on a Ficoll-Hypaque gradient. CD4+ T cells were isolated from PBMCs 
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using a negative selection method (CD4+ T cell Isolation Kit II, Miltenyi Biotec). 
Resting CD4+ lymphocytes (CD4+, CD69–, CD25– and HLA-DR–) were enriched by a 
second negative depletion (CD25-Biotin; Anti-Biotin MicroBeads; CD69 MicroBead Kit 
II; Anti–HLA-DR MicroBeads, all from Miltenyi Biotec). Resting CD4+ cell purity was 
consistently >95% as assessed using flow cytometry.  
DNA extraction and limiting dilution PCR 
DNA was extracted from 2 x 106 resting CD4+ cells using the Qiagen Gentra 
Purgene Cell Kit A, which allows for extraction of large fragments of ~200kb in size so 
as to minimize fragmentation of HIV-1 genomes. DNA was subjected to a nested limiting 
dilution PCR protocol modified from Ho et al. using Platinum Taq HiFi Polymerase (Life 
Technologies) (Ho et al., 2013a). The outer PCR was nearly full-length from HXB2 
coordinates 623 to coordinates 9,686 and employed a touchdown PCR protocol. The 
outer PCR wells were diluted 1:3 with DI water and 1µL of outer PCR DNA was used for 
nested amplification of both gag and env to determine clonality. Clonality was 
determined using Poisson statistics and at dilutions giving a high probability of clonality 
(P > 0.85), all outer PCR wells, including those that were negative for gag and env, were 
subjected to six inner PCRs. 1µL of outer PCR DNA was used for each nested PCR 
reaction. A detailed PCR protocol and primer sequences and locations can be found in 
Table 2.2. PCR products were visualized on 1% agarose gels. The products were directly 
sequenced to minimize PCR-induced error using the QIAquick Gel Extraction Kit 
followed by Sanger sequencing. Sequencing reads from the six overlapping nested PCRs 
were aligned and compared to the reference genome HXB2 using CodonCode Aligner 
software to reconstruct near full-length sequences and identify defects. Hypermutation 
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was determined using the full-length sequence for each clone and the Los Alamos 
hypermut algorithm (Rose and Korber, 2000). Some hypermutated clones had extensive 
hypermutation that prevented full sequencing of the entire genome. Since the PCR 
products were correctly sized on an agarose gel, the sequences were inferred to be full-
length hypermutated. We were able to directly map the majority of deletions by direct 
sequencing of PCR products generated with primers flanking the deletion junction. Some 
very large internal deletions were identified despite deletion of some inner primer binding 
sites. Observed bands likely resulted from exponential amplification in the outer PCR and 
linear amplification in inner PCRs. These deletions were confirmed through sequencing 
bands from multiple inner PCRs, all of which showed the exact same deletion product.  
In vitro infections 
HIV-1 negative donor CD4+ T cells were isolated as above and activated with 
phytohaemagglutinin (PHA) (0.5µg/mL) for 3 days in IL2-containing medium (Kim et 
al., 2014). Cells were infected with replication-competent HIV-1 Ba-L virus (300 ng 
p24/106 cells) by spinoculation (2 hrs, 37°C, 1200 x g). Cells were then suspended at 3 x 
106/mL in IL2-containing medium and incubated for 6 days at 37°C. Following the 
incubation, supernatant was collected, and stored at -80°C. 25 x 106 HIV-1 negative 
donor CD4+ T cells were activated by αCD3/αCD28 stimulation for 72 hours in IL-2-
containing medium as previously described (Kim et al., 2014). Activated cells were 
suspended in 2.5mL of IL-2-containing medium and distributed in 100µL aliquots into a 
96-well v-bottom plate. A 500ng inoculum of HIV-1 Ba-L was added to each well and 
cells were infected by spinoculation (2hrs, 37°C, 1200 x g). Following the spinoculation, 
cells were suspended in 40mL of IL2-containing medium supplemented with enfuvirtide 
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(10uM) to prevent additional rounds of viral replication. Following a two day incubation 
at 37°C, genomic DNA was isolated and analyzed as above. 
Quantitative viral outgrowth assay  
The QVOAs were performed as previously described (Finzi et al., 1997; Laird et 
al., 2013; Siliciano and Siliciano, 2005). MOLT-4/CCR5 cells were added on Day 2 of 
the culture (Laird et al., 2013) and the culture supernatants were examined using the 
standard protocol, which involves an ELISA for the p24 viral capsid protein 
(PerkinElmer) after 21 days. HIV-1 RNA in the culture supernatant was not measured. 
MOLT-4/CCR5 cells were obtained from NIH AIDS reagent program, were negative for 
mycoplasma contamination, and were stained to verify expression of CD4, CXCR4, and 
CCR5.  Infectious units per million cells (IUPM) values were calculated using 
IUPMStats (Rosenbloom et al., 2015). If all culture wells were negative for viral 
outgrowth, the median posterior estimate of infection frequency was used. 
Droplet digital PCR 
DNA was extracted from 5-10 x 106 resting CD4+ T cells using the QIAamp 
DNA Blood Mini Kit. DNA was fragmented and a duplex droplet digital PCR was 
performed with primers in the gag gene as well as primers for 2LTR circles as previously 
described (Massanella et al., 2015; Strain et al., 2013). For pt. 2609, primers in the pol 
gene were used instead as the gag PCR primers and probes contained multiple 
mismatches with the patient sequence and did not amplify (Massanella et al., 2015). 
Measurements of the cellular gene RPP30 in a replicate well by ddPCR were used to 
calculate the frequency of resting CD4+ T cells. The frequency of gag+ DNA and 2LTR 
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circles were plotted as a frequency per 106 resting CD4+ T cells. In the case of a negative 
2LTR circle measurement, the lower limit of detection was determined using the total 
cellular input for that sample. Since many of the proviruses examined were gag negative, 
we also estimated the total number of infected cells in study subject resting CD4+ T cells 
as the copies of gag+ proviral DNA divided by the fraction of proviruses detected that 
were gag+. For Pt. 2609 the total number of infected cells was estimated as the copies of 
pol+ proviral DNA divided by the fraction of proviruses detected that were pol+ since the 
gag PCR primers did not amplify.   
Bayesian analysis to calculate number of intact proviruses 
The proportion of intact genomes for each subject was estimated using an 
Empirical Bayesian analysis, with prior distributions generated separately for the acute 
and chronic subject cohorts. The proportion of clones identified as intact was calculated 
for each subject, and the mean and variance of this measurement were used to generate 
beta prior distributions with the same mean and variance. The proviral genome sequences 
were treated as Bernoulli trials, with intact clones counted as successes. The final 
estimate for the percent of intact genomes for each subject was calculated as the expected 
value of the posterior distribution. The number of intact proviruses was calculated as the 
frequency of cells with total HIV-1 DNA times the frequency of intact proviruses 
estimated for each subject using an empirical Bayesian model.  
Correlation plots 
All data sets except the percent of intact proviruses followed a log distribution 
and were log transformed. The log transformed data met the D’Agostino-Pearson test for 
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normal distribution, and Pearson correlations were performed on log transformed data. 
For the QVOA data in which one of the samples was below the limit of detection, the 
median posterior estimate of infection frequency was plotted instead. P < 0.05 was 
considered statistically significant. GraphPad Prism software was used to perform all 




2.5 Tables: Chapter 2  










































2453	 59	 M	 W	 TDF/FTC,	NVP	 134	 133	 130	 24	 <50	
2454	 34	 M	 W	 TDF/FTC/RPV	 85	 84	 77	 17	 <50	
2443	 52	 M	 W	 TDF/FTC/EVG/COBI	 80	 79	 70	 29	 <50	
2529	 32	 M	 AS	 TDF/FTC/RPV	 29	 26	 25	 97	 <50	
2521e	 47	 M	 W	 TDF/FTC,	DGV	 17	 15	 8	 53	 <50	
3693	 46	 M	 W	 TDF/FTC,	DGV	 11	 10	 9	 25	 <50	
2286	 49	 M	 W	 TDF/FTC/RPV	 147	 145	 142	 39	 <50	
2609	 33	 M	 W	 ABC/3TC/DTG	 26	 24	 20	 50	 <50	
2531	 40	 M	 W/LA	 TDF/FTC,	RAL	 34	 32	 28	 57	 <50	
CP01	 64	 M	 LA	 TDF,	3TC,	ETR	 >179	 130	 127	 >180	 <50	
CP02	 61	 M	 AA	 ABC/3TC,	DRV/r,	RAL	 131	 89	 58	 >180	 <50	
CP03f	 76	 M	 W	 ABC/3TC,	ATV/r	 >194		 192	 191	 >180	 <50	
CP04	 49	 F	 AA	 TDF/FTC/EFV,	DRV/r	 322	 210	 129	 >180	 <50	
CP05	 56	 F	 AA	 ABC,	FTC,	ETR,	RAL	 >214	 >187	 31	 >180	 <50	
CP06	 64	 M	 W	 ABC,	FTC,	ETR		 >263	 >203	 103	 >180	 <50	
CP07	 36	 M	 N/A	 TDF/FTC/EFV	 >124	 65	 55	 >180	 <50	
CP08	 45	 M	 AA	 ETR,	MVC,	RAL	 >131	 >53	 16	 >180	 <50	
CP09	 45	 M	 AA	 3TC,	DRV/r,	RAL	 311	 132	 103	 >180	 <50	
CP10	 58	 M	 AA	 ETR,	DRV/r,	RAL	 261	 >189	 91	 >180	 <50	
VM01	 33	 M	 AA	 TDF/FTC/EFV	 137	 106	 -	 >180	 4,719	
VM02	 20	 M	 AA	 -	 unknown	 -	 -	 -	 101,484	
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Supplementary Table 2. PCR Primers and conditions 
 









9,064 BLOuterF 623 – 
649 
AAATCTCTAGCAGTGGCGCCCGAACAG 10 m 







5GagIn 836 – 857 GGGAAAAAATTCGGTTAAGGCC 1 m 30 s 
















275F 646 – 666 ACAGGGACCTGAAAGCGAAAG  5 m 
3INOut 5,072 – 5,094 AATCCTCATCCTGTCTACTTGCC  
B 5,793 
263F 651 – 672 GACCTGAAAGCGAAAGGGAAAC 6 m 
3AccOut 6,421 – 6,443 GGCATGTGTGGCCCARAYATTAT 
C 6,385 
5INOut 3,248 – 3,270 ACTCCATCCTGATAAATGGACAG  6 m 30 s 
BLInnerR 9,604 – 9,632 GCACTCAAGGCAAGCTTTATTGAGGCTTA  
D 4,778 
5AccOut 4,899 – 4,922 CGGGTTTATTACAGGGACARCARA 5 m 
280R 9,650 – 9,676 CTAGTTACCAGAGTCACACAACAGACG 
 
Outer PCR cycling conditions: 
94°C for 2 m; then 94°C for 30 s, 64°C for 30 s, 68°C for 10 m for 3 cycles; 94°C for 30 s, 61°C 
for 30 s, 68°C for 10 m for 3 cycle; 94°C for 30 s, 58°C for 30 s, 68°C for 10 m for 3 cycle; 94°C 
for 30 s, 55°C for 30 s, 68°C for 10 m for 21 cycle; then 68°C for 10 m. (30 total cycles) 
Inner PCR cycling conditions: (X = extension time from the table above)  
94°C for 2 m; then 94°C for 30 s, 64°C for 30 s, 68°C for X m for 3 cycles; 94°C for 30 s, 61°C 
for 30 s, 68°C for X m for 3 cycle; 94°C for 30 s, 58°C for 30 s, 68°C for X m for 3 cycle; 94°C 
for 30 s, 55°C for 30 s, 68°C for X m for 36 cycle; then 68°C for X m. (45 total cycles) 
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2.6 Figures: Chapter 2 
Figure 2.1 Full Genome Sequencing Method for Proviral DNA 
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(a) Schematic of strand transfer events during reverse transcription relative to the HIV-1 
genome. Deletions occur during minus strand synthesis before the second strand transfer 
event by the same copy choice mechanism that leads to recombination (Hwang et al., 
2001). (b) Unbiased full genome sequencing strategy based on mechanistic 
considerations in (a) to capture the majority of defective proviruses. Bands from 








(a) Maps of proviral clones from three representative subjects treated during the chronic 
phase of infection. Each horizontal bar represents an individual clone identified through 
full genome sequencing. In cases where a deletion could not be precisely mapped due to a 
deletion encompassing multiple forward or reverse primer binding sites, the possible 
maximum and minimum deletions sizes are plotted (in grey). If sequencing data shows a 
mapped deletion that removes primer-binding sites for other amplicons, the resulting 
missing sequence was inferred to be present (light blue or green). A pink arrow denotes 
full-length, genetically intact sequences. Black asterisks indicate likely full-length 
hypermutated proviruses that were not fully sequenced due to extreme hypermutation.  
See Figure 2.3 for maps of proviruses from seven additional subjects. (b) Summary of 
152 proviral sequences. (c) Short repeats (underlined) identified on both ends of the 
deletion junctions are consistent with a copy choice mechanism of recombination 
resulting in deletion of the intervening sequence and one homology region (/number of 
basepairs deleted/).  
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Sequence maps of proviral clones from seven additional subjects treated during the 
chronic phase of infection. Each horizontal bar represents an individual clone identified 
through full genome sequencing. In cases where a deletion could not be precisely 
mapped, likely due to a deletion encompassing multiple forward or reverse primer 
binding sites, the maximum and minimum deletions sizes are plotted (in grey). If 
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sequencing data shows a mapped deletion that removes primer-binding sites for other 
amplicons, the resulting missing sequence was inferred to be present (light blue or green). 
A pink arrow denotes full-length, genetically intact sequences. Black asterisks indicate 




Figure 2.4 Deletions are nonrandom and occur at hotspots in the HIV-1 genome 
 
 
(a) Distribution of deletions in subject sequences. Each horizontal line indicates a unique 
proviral deletion from a clone identified by near full-length genome sequencing. 
Sequences from all treated subjects (acute/early and chronic phase) are included. In cases 
of identical (expanded) clones, only one clone was included in this analysis. For proviral 
clones with multiple deletions, one horizontal bar is shown for each deletion. Blue and 
red circles indicate the 5' and 3' ends of the deletion, respectively. (b) Distribution of the 
5' (blue) and 3' (red) ends of the deletions. Hotspots for deletions, indicated by spikes in 
the frequency distributions, may be related to structural features in the RNA genome.  























Figure 2.5 High proportion of hypermutated sequences contain mutated start codons 
and premature stop codons 
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(a) Fraction of hypermutated sequences that contain a functional start codon for each 
HIV-1 gene. The ATG and second codon as well as the translated amino acid sequence 
are shown in blue. Sequences with G to A hypermutation by APOBEC3F/G affecting the 
ATG start codon are shown in red and orange with hypermutated nucleotides underlined. 
An asterisk denotes other types of mutations affecting the start codon (frameshift 
mutation, etc). Hypermutated sequences were identified using the Los Alamos hypermut 
algorithm (Rose and Korber, 2000). This analysis was performed on all unique 
hypermutated sequences from acute and chronic phase subjects for which the relevant 
start codon was present. n indicates the number of sequences analyzed. (b) Frequency of 
hypermutated sequences that contain internal, premature stop codons in each HIV-1 gene. 
Wild type (blue) sequences contained no premature stop codons, and mutated (red) 
sequences contained 1-50 premature stop codons per gene. (c) Frequency of 
hypermutated sequences that contain functional or defective copies of each HIV-1 gene. 
Proviruses with both an intact start codon and no internal stop codons were relatively rare 
and were considered to make a functional copy of a given gene (blue). The remaining 
proviruses contained defective copies of a given gene and had a functional start codon but 
contained internal stop codons (yellow), a mutated start codon but no internal stop codons 
(orange) or contained both a mutated start codon and internal stop codons (red). 
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Figure 2.6 2-LTR circles are present at low levels in resting CD4+ T cells of subjects 




(a) 2-LTR circles were measured by ddPCR (Massanella et al., 2015; Strain et al., 2013). 
The cellular gene RPP30 was measured in a replicate well by ddPCR and used to 
calculate the total number of cells. Levels of 2-LTR circles were expressed as a 
frequency per 106 resting CD4+ T cells. In cases where no 2-LTR circles were detected 
(represented by an open symbol), the limit of detection is plotted as determined by the 
cellular input for that sample. (b) Frequency of 2-LTR circles relative to the total number 
of proviruses. The number of 2-LTR circles was measured as in (a) and was normalized 
to the total number of proviruses per 106 resting CD4+ T cells. The predicted total 
number of proviruses was calculated for each subject by correcting the gag ddPCR result 





























































































(a—c) Maps of independent proviral clones. Each horizontal bar represents an individual 
clone identified through full genome sequencing. In cases where a deletion could not be 
precisely mapped, likely due to a deletion encompassing multiple forward or reverse 
primer binding sites, the maximum and minimum deletions sizes are plotted (in grey). If 
sequencing data shows a mapped deletion that removes primer-binding sites for other 
amplicons, the resulting missing sequence was inferred to be present (light blue or green). 
A pink arrow denotes full-length, genetically intact sequences. Black asterisks indicate 
likely full-length hypermutated proviruses that were not fully sequenced due to extreme 
hypermutation.   (a) Sequences from resting CD4+ T cells of three representative subjects 
treated during acute/early infection (9 subjects total studied). For additional acute/early 
subject sequences, see Fig. 2.8. (b) Sequences identified following a single round of in 
vitro infection of healthy donor CD4+ T lymphoblasts with HIV-1 (Ba-L isolate). (c) 
Sequences from CD4+ T cells from viremic subjects in the chronic phase of infection. (d) 
Summary of all proviral sequences identified from each study population.    
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Figure 2.8 Characterization of proviral sequences in subjects initiating ART during 
acute/early infection 
 
Sequence maps of proviral clones from six additional subjects treated during the 
acute/early phase of infection. Each horizontal bar represents an individual clone 
identified through full genome sequencing. In cases where a deletion could not be 
precisely mapped, likely due to a deletion encompassing multiple forward or reverse 
primer binding sites, the maximum and minimum deletions sizes are plotted (in grey). If 
sequencing data shows a mapped deletion that removes primer-binding sites for other 
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amplicons, the resulting missing sequence was inferred to be present (light blue or green). 
A pink arrow denotes full-length, genetically intact sequences. Black asterisks indicate 




Figure 2.9  Acutely-treated subjects have a higher fraction of hypermutated proviruses 
and a lower fraction of deleted proviruses than chronically-treated subjects. 
 
(a,b,c) Sequences were obtained by near full-length genome sequencing performed at 
limiting dilution. Horizontal bars indicate median values. Statistical significance was 
determined using a two-tailed unpaired t-test. The variance between groups was not 
statistically different. (a) The fraction of intact sequences was calculated by dividing the 
number of intact clones by the total number of clones observed for each subject. (b) The 
fraction of hypermutated sequences was calculated as described in (a) but using the 
number of hypermutated clones instead of the number of intact clones. Hypermutation 
was determined for each sequence by the Los Alamos hypermut algorithm (Rose and 
Korber, 2000). (c) The fraction of deleted sequences was calculated as described in (a) 








































































































Figure 2.10 Expanded clones are present in many chronically or acutely treated 
individuals 
 
(a,b) Proportion of sequences from subjects treated during acute (a) or chronic (b) 
infection that are expanded clones. The number of sequences examined for each subject 
(n) is noted. Expanded clones (purple/blue) are shown as a percentage of total sequences 
from the relevant subject. Colored boxes denote the subject in which each expanded 
clone was identified (see Fig. 2.11a,b).  
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(a,b) Maps of expanded HIV-1 clones identified in resting CD4+ T cells from subjects 
treated in acute (a) or chronic (b) infection. Expanded clones are defined as clones 
amplified in completely independent PCR reactions from a single subject that are 
identical at every nucleotide. The frequency of each clone is shown relative to the total 
number of clones identified in that subject. Colored boxes denote the subject in which 
each expanded clone was identified (see Fig. 2.10a,b). 
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Figure 2.12  Current assays significantly underestimate or overestimate the size of the 
latent reservoir 
	
(a,b) Comparison of different reservoir measurements in resting CD4+ T cells from 
subjects starting ART during chronic (a) or acute (b) infection. The frequency of infected 
cells was measured by QVOA, which detects cells that release infectious virus after one 
round of T cell activation and is reported as the number of infectious units per million 
resting CD4+ T cells (IUPM). For individuals in whom the IUPM was below the limit of 
detection, the median posterior estimate of infection frequency was plotted instead (open 






















































































































































































































































































correcting the ddPCR result (gag+ proviruses) for the fraction of proviruses with deletions 
in gag. The frequency of cells with intact proviruses was calculated as the frequency of 
infected cells times the fraction of intact proviruses estimated for each subject using an 
empirical Bayesian model. Open symbols indicate subjects in which no intact proviruses 
were detected. Horizontal bars indicate median values. Statistical significance was 
determined using a two-tailed paired t-test and the variance was similar between groups.  
*P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. (c) Underestimation of the 
latent reservoir size by the QVOA was calculated by dividing the number of intact 
proviruses by the QVOA result for each subject. Overestimation of the latent reservoir 
size by DNA PCR was calculated by dividing the gag+ provirus PCR values by the 
number of intact proviruses. Horizontal bars indicate median values. (d,e) Comparison of 
infected cell frequencies as determined by QVOA (pink), analysis of intact proviruses 
(yellow), and ddPCR for gag+ proviral DNA (blue) for three representative CP- (d) and 
AP- treated (e) subjects. All values are plotted as a percentage of the frequency of cells 
with gag+ proviral DNA. The number of gag+ proviruses per million resting CD4+ T cells 
as measured by ddPCR is indicated in parenthesis for each subject. For additional subject 
comparison plots, see Fig. 2.14.  
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Figure 2.13  The number of intact proviruses does not correlate well with current 
assays 
	
(a) Pearson correlation between the number of intact proviruses and the frequency of 
infected cells as measured by the QVOA (IUPM). The number of intact proviruses was 
calculated as the frequency of infected cells times the fraction of intact proviruses 
estimated for each subject using an empirical Bayesian model. Open symbols indicate 
subjects in which no intact proviruses were detected. (b) Pearson correlation between the 
fraction of intact proviruses and the frequency of cells with gag+ proviruses as 
determined by ddPCR (Massanella et al., 2015; Strain et al., 2013). (c) Pearson 
correlation between the IUPM and frequency of cells with gag+ proviruses as measured 
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(a,b) Comparison of IUPM (pink), number of intact proviruses (yellow), and gag+ 
proviral DNA (blue). All values are plotted as a percentage of the frequency of cells with 
gag+ proviral DNA. The number of gag+ proviruses per million resting CD4+ T cells as 
measured by ddPCR is indicated in parenthesis for each subject. (a) Comparison for 
subjects treated during chronic infection (b) Comparison for subjects treated during 
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Chapter 3. A novel droplet digital PCR-based assay for quantifying 
genetically intact HIV-1 proviruses 
3.1 Introduction 
HIV-1 preferentially infects activated CD4+ T cells, most of which die via viral 
cytopathic effects or are cleared by the adaptive immune response. A small fraction of 
activated CD4+ T cells transition from an activated state to a resting memory state, 
generating long-lived adaptive immunologic memory. When activated CD4+ T cells that 
are HIV-1 infected undergo this transition, HIV-1 gene expression largely ceases and the 
integrated, infectious virus persists as silent integrated genome (Chun et al., 1997a; Finzi 
et al., 1997; 1999; Wong et al., 1997b). Latently infected cells are present in all infected 
patients, are not targeted by antiretroviral therapy (ART) (Chun et al., 1997a; Finzi et al., 
1997; 1999; Wong et al., 1997b), and persist for the lifetime of infected individuals 
(Crooks et al., 2015; Finzi et al., 1999; Siliciano and Siliciano, 2005). Because these 
latently infected cells act as a long-term reservoir for infectious virus, patients must 
remain on lifelong ART to prevent rebound in viral replication and disease progression, 
which typically occurs within weeks of stopping therapy (Crooks et al., 2015; Finzi et al., 
1999; Siliciano and Siliciano, 2005). The latent HIV-1 reservoir is recognized as the 
primary barrier to curing HIV-1 infection.  
An international effort is underway to eliminate latent HIV-1 and cure the 
infection	 (International AIDS Society Scientific Working Group on HIV Cure et al., 
2012). A number of drug candidates targeting latent HIV-1 have been tested in Phase I 
clinical trials (Archin et al., 2012a; 2014; Rasmussen et al., 2014a; Søgaard et al., 2015; 
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Wei et al., 2014), and many more are in development (Xing and Siliciano, 2013). 
However, therapeutic development is severely hindered by the lack of an accurate, rapid, 
and scalable test to measure latent HIV-1 in a clinical setting (Crooks et al., 2015). 
The measurement of latent HIV-1 is technically challenging. The Siliciano Lab 
originally developed the first method for detecting latent HIV-1 using the quantitative 
viral outgrowth assay (QVOA) (Finzi et al., 1997; Siliciano and Siliciano, 2005). This 
assay requires 180 mL of patient blood and relies on two to three weeks of expansion of 
infectious HIV-1 in tissue culture to detect latent HIV-1. A more rapid version of the 
QVOA, requiring only a single week of HIV-1 expansion has also been developed (Laird 
et al., 2013), however neither version of the QVOA is scalable for clinical use. Recent 
studies have further shown that the QVOA underestimates the true size of the latent 
reservoir by 25 to 62 fold (Bruner et al., 2016; Ho et al., 2013a). The design of an 
accurate PCR-based molecular assay to measure latent HIV-1 is also technically 
challenging, primarily due to the abundance of defective HIV-1 DNA present in memory 
CD4+ T cells (Bruner et al., 2016; Ho et al., 2013a), obscuring the measurement of intact, 
latent HIV-1. As such, current PCR-based assays measuring total HIV-1 DNA 
overestimate the size of the LR by approximately 188-fold and cannot specifically 
measure latent HIV-1 (Bruner et al., 2016). 
To overcome the critical technical hurdles of standard DNA PCR we designed the 
intact proviral DNA assay (IPDA). In this assay, we use multiplex digital droplet PCR to 
specifically detect and quantify genetically intact, latent HIV-1. We analyzed hundreds of 
full genome sequences from multiple well characterized cohorts (Bruner et al., 2016; Ho 
et al., 2013a; Imamichi et al., 2016). Through this analysis we identified regions and 
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features of the HIV-1 genome that, when interrogated simultaneously, specifically 
distinguish intact HIV from defective genomes. 	
3.2 Results 
We first analyzed full genome sequences from 22 individuals on suppressive ART 
to determine if a single, strategically placed PCR amplicon could provide discrimination 
between genetically intact and defective HIV-1 genomes. We performed a sliding 
window analysis across the HIV-1 genome and determined that defective genomes made 
up greater than 85% of all the sequences measured by any given amplicon, regardless of 
where the primers were placed in the genome (Fig. 3.1a). Since proviruses with large 
internal deletions comprise 58-80% of all proviruses and deletions cluster in specific 
regions of the HIV-1 genome (Bruner et al., 2016), we assessed whether two strategically 
placed amplicons interrogated simultaneously could provide substantially better 
discrimination between genetically intact and defective HIV-1 genomes than a single 
amplicon alone. Our analysis indicated that there were many possible two amplicon 
combinations that when interrogated simultaneously would correctly identify greater than 
80% deleted proviruses as defective (Fig. 3.1b). However, we found that an assay with 
primers in the packaging signal and a second set placed in certain regions of the env gene 
would identify 90% of deleted proviruses as defective (Fig. 3.1b).  
Proviruses containing G to A hypermutation comprise 15-31% of all proviruses 
(Bruner et al., 2016). These inactivating G to A mutations result from cytidine 
deamination on the HIV-1 minus strand by APOBEC3F or 3G during reverse 
transcription and can result in in-frame stop codons in viral ORFs (Yu et al., 2004). 
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Hypermutation frequency directly correlates with HIV reverse transcription dynamics 
and regions that remain single stranded the longest have the highest rates of 
hypermutation. This occurs upstream of the HIV-1 poly purine tracts (PPT) and portions 
of the env and the nef genes have particularly high levels of hypermutation (Kieffer et al., 
2005). Since there was relative flexibility in the placement of the 3’ amplicon (Fig. 3.1b), 
we chose the rev response element (RRE), a highly conserved region of the env gene, to 
place our second amplicon of the IPDA. To discriminate hypermutated from intact 
proviruses in the IPDA, we employ two hydrolysis probes targeting the same position in 
the HIV-1 genome. One probe is designed against the non-hypermutated sequence and is 
labeled, producing a fluorescent signal when an intact sequence is present. The other 
probe is designed against the hypermutated sequence and is labeled with a fluorophore 
that is not detectable by ddPCR. It binds to hypermutated sequences to prevent labeled 
probe binding and thus prevent fluorescent signal (Fig. 3.2a).  
To maximize effective hypermutation discrimination and optimize placement of 
the second IPDA amplicon, we performed an analysis of hypermutated genomes from 
HIV-1 infected individuals on suppressive ART. We identified 21% of proviruses with 
APOBEC3F, 14% with APOBEC3G, and 65% with both APOBEC3F and 3G 
hypermutation signatures (Fig. 3.2b). Since none of the non-deleted hypermutated 
sequences we examined contained only APOBEC3F hypermutation (Fig. 3.2b), we chose 
to focus on APOBEC3G hypermutation for our hypermutation discriminating probes, 
which was found in 79% of hypermutated genomes (Fig 3.2b). We identified three 
potential regions in the RRE of env that contained two APOBEC3G consensus sites 
within the length of a standard hydrolysis probe (Fig. 3.2c). One of these regions was 
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consistently hypermutated at both APOBEC3G consensus sites in 95% of hypermutated 
sequences and had a favorable G/C content for suitable probe design. Thus this region 
was selected for the second amplicon of the IPDA (Fig. 3.2c).  
We next examined the probe binding region for the second amplicon of the IPDA 
in 67 hypermutated sequences obtained through full genome sequencing from 15 donors 
(Bruner et al., 2016). We also performed additional in-depth sequencing of the env gene 
in 4 additional patients to include multiple hypermutated sequences from the same 
individual. We found that the specific nucleotides that were mutated varied from 
sequence to sequence. The most common hypermutation variant, present in 36% of 
hypermutated sequences, was a single G to A mutation at the first G of each of the TGGG 
sites, CCTTAGGTTCTTAGGA (Table 3.1). An additional 23% of hypermutated 
sequences contained two G to A mutations at the first two G nucleotides in the TGGG 
sites CCTTAAGTTCTTAAGA. Other variations of one to three G to A mutations at each 
APOBEC3G consensus sites were also observed and the sequences and relative 
frequencies are summarized in Table 3.1. To test how our hypermutation discrimination 
probes performed on these different hypermutation patterns found in HIV-1 infected 
individuals, we performed site directed mutagenesis of NL4-3 or a patient derived 
plasmid (Ho et al., 2013a) to create the different hypermutated sequence patterns shown 
in Table 3.1. We performed qPCR on all the constructs using the hypermutation 
discrimination probes and looked for the signal or absence of signal from the intact and 
hypermutated probes. The wildtype (intact) probe bound to and fluoresced in less than 
5% of the hypermutated sequences. These hypermutated sequences either contained a 
single mutation at only one of the APOBEC3G consensus sites or were not mutated at 
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either APOBEC3G site in the probe binding region and were an exact match to the probe 
sequence (Table 3.1), thus it is not surprising that the intact probe bound.  We also 
determined that the hypermutated probe bound to the hypermutated sequences that were 
an exact match in sequence, CCTTAGGTTCTTAGGA as well as the sequences that 
were different by a single mutation, either by an addition of another APOBEC3G G to A 
mutation, CCTTAAGTTCTTAGGA or CCTTAGGTTCTTAAGA or by one fewer G to 
A mutation, CCTTGGGTTCTTAGGA or CCTTAGGTTCTTGGGA. For sequences that 
were negative for both probe signals, we ran the qPCR products on a gel to verify the 
presence of a band. This was to confirm that the PCR reaction itself was successful and 
that lack of fluorescence was due to probe/template mismatches (data not shown). In the 
IPDA ddPCR reaction, the hypermutated probe is unlabeled thus only sequences that 
bind to an intact probe will fluoresce. We determined that the IPDA ddPCR will 
incorrectly identify, at most, only 5% of hypermutated sequence as intact (Table 3.1).  
Additionally, we verified the sequence conservation of the primer and probe sets 
selected for the IPDA. Both sets were highly conserved, as determined by analysis 
against the Los Alamos National Laboratories HIV Sequence Database. The individual 
reactions are equivalent in amplicon size, G/C content, and required melt temperature. 
Primer entropy analysis did not reveal a risk of primer or probe dimerization. NCBI 
BLAST analysis was performed and showed no risk of non-specific amplification. This 
was confirmed by the absence of amplification by either primer set when genomic DNA 
from uninfected donors was used as template. Based on these analyses, we are confident 
we have optimized the IPDA primers and probes. 
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In the IPDA, CD4+ T cells are isolated from PBMCs from a standard blood draw 
of 30 mL (Fig. 3.3). The next step in sample processing is the isolation of human 
genomic DNA (gDNA). The isolation of gDNA causes shearing of intact chromosomal 
DNA into fragments, and the size and distribution of these fragments depends upon the 
isolation procedure employed. In the IPDA, individual HIV-1 proviruses are partitioned 
into individual droplets using ddPCR and are analyzed simultaneously at two regions of 
the genome via multiplex PCR (Fig. 3.3). Droplets containing intact proviruses are 
identified by successful PCR amplification at both regions (Fig. 3.4). The size and 
distribution of gDNA fragmentation can therefore significantly impact the performance 
of the IPDA. With increasing amounts of gDNA fragmentation, the probability of 
shearing intact proviruses during isolation increases, thus leading to increased numbers of 
false-negative droplets and artificial lower counts of intact HIV-1 proviruses. Conversely, 
droplet formation and DNA loading per reaction is hindered by high molecular weight 
gDNA with minimal fragmentation. Thus, we sought to optimize the balance between 
DNA fragmentation and shearing of proviruses while maximizing DNA loading per 
reaction well for ddPCR.   
The likelihood of shearing an intact provirus using a gDNA isolation protocol 
which produces a set size and distribution of gDNA fragments can be defined using 
Poisson statistics. The distance between the two amplicons in the IPDA ddPCR reaction 
is 7,159bp. We therefore used Poisson statistics to determine the proportion of intact 
proviruses that would survive gDNA isolation without shearing between these regions 
(Fig. 3.5a). Given an average DNA extraction fragment size of 20-30kb with fragments 
up to 50kb in size from the QIAamp DNA mini extraction kit, these statistical predictions 
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predict that 75-80% of the genomes will remain intact and unfragmented. To validate 
these statistical predictions, we designed two control primer/probes sets in the RPP30 
gene spaced approximately the same distance as the packaging signal and env HIV-1 sets 
(Fig. 3.5b). We extracted gDNA from uninfected donors using the QIAamp DNA mini 
extraction kit and performed the multiplex RPP30 assay on the cells. We found that on 
average 74% of the genomes remained unsheared following DNA extraction and PCR 
amplification in the ddPCR reaction. This result was reproducible in 3 technical 
replicates from 4 donors indicating that the amount of fragmentation per gDNA 
extraction is consistent (Fig. 3.5c). We are in the process of optimizing the DNA 
extraction process to minimize shearing to the HIV-1 genomes in the IPDA.  
We validated the specificity of the IPDA ddPCR using plasmid controls 
containing patient-derived proviral sequence from previous studies (Bruner et al., 2016; 
Ho et al., 2013a). We used plasmids containing a 5’ deletion, 3’ deletion, hypermutated 
genome or intact genome and measured them alone or in combination using the IPDA. 
The plasmid controls showed the specificity of the IPDA reaction. The 5’ deletion 
plasmid was single positive for the env amplicon (Fig. 3.6a) and the 3’ deletion plasmid 
(Fig. 3.6b) and the hypermutated plasmid (Fig. 3.6c) were single positive for the 5’ 
amplicon. The intact NL4-3 plasmid showed mostly double positive droplets (Fig. 3.6d). 
Approximately 5% of the reaction droplets were single positive instead of double 
positive, most likely due to degradation of the plasmid over time. Additionally, we tested 
the plasmids in combination by diluting the NL4-3 intact plasmid into mixtures of 
defective plasmids to mimic a patient sample. We held the amounts of 5’ and 3’ deletion 
plasmids constant at 1,000 copies each and diluted 1,000 copies (Fig. 3.7a), 100 copies 
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(Fig. 3.7b) and 10 copies (Fig. 3.7c) of NL4-3 into the mixture of defective plasmids. In 
each case, we observed the expected ratio of defective to intact sequence.  
We next experimentally assessed the linearity, specificity, and limit of detection 
of the IPDA on ddPCR. IPDA reactions were performed using either NL4-3 plasmid 
alone, or NL4-3 spiked into healthy donor gDNA isolated with our optimized protocol. 
To mimic the range of intact provirus quantities typical of HIV-1 infected patient 
samples, we spiked NL4-3 in a half-log dilution series ranging from 10,000 copies to 3 
copies. We observed strong agreement between the predicted and observed NL4-3 copy 
numbers detected across the entirety of the dilution series in both the plasmid only and 
plasmid in healthy donor gDNA reactions (Fig. 3.8a). Additionally, we tested an HIV-1 
cell line (5b5) that contained one provirus per cell in the same dilution series, with and 
without additional gDNA added (Fig. 3.8b). Linear regression analysis of both dilution 
curves indicate that the reactions were linear. A lack of amplification in negative control 
wells along with the concordance of NL4-3 or HIV-1 cell line copy numbers measured in 
both the presence and absence of healthy donor gDNA clearly demonstrate that our 
ddPCR reaction is specific (Fig. 3.8a,b). We were able to detect 3 copies per reaction, 
which was our lowest spiked template concentration, suggesting that our limit of 
detection is approximately 3 copies. These data clearly demonstrate that our optimized 
IPDA reaction performs well and is reproducible and linear.  
Using the banked samples from HIV-1 infected individuals we had previously 
characterized using full-genome sequencing and/or the QVOA (Bruner et al., 2016), we 
performed pilot IPDA measurements on 14 HIV-1 infected patients on ART (Fig. 3.9). 
The majority of these pilot experiments were performed using an older version of the 
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IPDA with primers in the gag gene instead of the packaging signal. The percent of intact 
sequences observed in these individuals is consistent with previously observed levels from 
full-genome sequencing (Bruner et al., 2016). For 8 of the 14 HIV-1 infected patients, we 
were able to assess the correlation between the IPDA and in-depth sequencing we had 
previously performed (Bruner et al., 2016) and found a statistically significant correlation 
(Pearson r=0.942, P=0.0005). It is important to note that we were able to detect intact 
proviruses in both chronic and acutely treated individuals. This indicates that the assay can 
be used in patients who initiated treatment early in infection and typically have smaller 
and more difficult to measure reservoirs. This initial correlation indicates that the IPDA 
effectively distinguishes and quantifies intact HIV-1 proviruses and warrants further 
studies with additional patient samples. 
3.3 Discussion 
Despite an international effort to eliminate latent HIV-1 and cure individuals 
infected with HIV-1, therapeutic development is currently hindered by the lack of an 
accurate and rapid test to measure latent HIV-1. An accurate measurement of intact HIV-
1 proviruses, currently the closest estimate to the true size of the latent reservoir, would 
be beneficial to both researchers and clinicians alike. While research assays currently 
exist, they either significantly underestimate or overestimate the size of the latent 
reservoir and are not scalable for clinical use.  
To address this critical need, we developed the intact proviral DNA assay (IPDA), 
a multiplex digital droplet PCR test capable of quantifying the amount of latent HIV-1 in 
infected patients.  Through an in-depth analysis of over 450 full-genome sequences of 
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latent HIV-1 from infected individuals, we identified specific HIV-1 genome features 
that, when interrogated simultaneously, specifically distinguish latent HIV-1 with intact 
genomes from defective ones. Preliminary results are highly encouraging. The percent of 
proviruses that are intact in patient samples is consistent with levels reported in previous 
studies. Preliminary data from eight patients for whom we also have full genome 
sequencing results shows a strong correlation between the IPDA readout and the 
percentage of genomes that are intact from full-genome sequencing. Currently, the IPDA 
reports the percentage of intact genomes relative to the proportions of defective genomes. 
Ongoing work consists of measuring a cellular gene in a replicate ddPCR reaction. This 
additional measurement will enable us to report the number of intact genomes per million 
resting CD4+ T cells, data which would be required to assess changes in the intact 
population of proviruses that would result from a therapeutic intervention.  
We have banked samples from ten patients treated during chronic infection and 
from eight patients treated during acute infection and have previously performed full 
genome sequencing, total HIV-1 DNA measurement by ddPCR and the QVOA on these 
banked samples (Bruner et al., 2016). We plan to compare this data to the final, 
optimized version of the IPDA, which will allow us to compare our new assay with the 
existing QVOA and total HIV-1 DNA PCR. Additionally, we can then determine whether 
there is a correlation between the IPDA and the number of intact proviruses observed 
from full-genome sequencing, which is likely the best benchmark in the absence of an 
accurate gold standard assay.  
Currently, standard single region PCR-based assays detect primarily defective 
proviruses with intact proviruses comprising less than 10% of what is measured with a 
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standard PCR in the gag gene, the most commonly used gene for DNA PCR 
measurements (Fig. 3.10). In contrast, the IPDA eliminates 90-95% of the defective 
proviruses and we predict that 70% of what is detected in the IPDA will be from intact 
proviruses (Fig. 3.10). Thus, by eliminating the majority of defective proviruses, which 
vastly outnumber intact proviruses (Bruner et al., 2016; Ho et al., 2013a; Imamichi et al., 
2016), our assay more accurately measures the true size of the latent reservoir present in 
an infected individual. Many defective proviruses contain defects that likely preclude 
elimination by eradication strategies and could obscure the measurement of real changes 
in the rarer intact proviruses. By measuring primarily intact proviruses, we anticipate our 
assay will better assess the impact of eradication strategies on the true reservoir of virus 
that must be eliminated to achieve an HIV-1 cure. 
3.4 Materials and Methods 
Study subjects 
The Johns Hopkins Institutional Review Board and the UCSF Committee on 
Human Research approved this study. All participants provided written consent prior to 
enrollment. Eight HIV-1 infected individuals who met the criteria of suppressive ART 
and undetectable plasma HIV-1 RNA level (< 50 copies per mL) for a minimum of 
months were enrolled. Two of these participants were recruited from the SCOPE and 
OPTIONS cohorts at the University of California, San Francisco. CP-treated subjects are 
defined as subjects starting ART >180 days from the estimated date of infection. AP-
treated subjects started ART < 100 days after the estimated date of infection. Table 2.1 
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details the characteristics of study participants, a subset of whom were used in these 
experiments.  
DNA extractions: 
DNA was extracted from 5x106 resting CD4+ T cells using the QIAamp DNA 
extraction kit following the manufacturer protocol (Qiagen). The DNA was eluted using 
100µL of AE buffer to concentrate DNA. The DNA concentration was estimated from 
the A260/A280 absorptivity ratio using a NanoDrop 2000 spectrophotometer (Thermo 
Scientific). Where specified, control templates were thoroughly mixed with 500ng of 
human genomic DNA. This DNA was obtained by identical extraction methods from the 
PBMCs of HIV negative donors. The DNA was not digested prior to ddPCR. A 
maximum of 750ng of DNA was loaded per ddPCR reaction well.  
Droplet digital PCR preparation and conditions:   
The hydrolysis probes used in the ddPCR reactions are very sensitive to freeze 
thaw and too many freeze thaw cycles impair assay performance. Probes were dispensed 
into 10uL aliquots immediately upon arrival and stored at -20C. Once a given aliquot was 
thawed, it was not refrozen or reused for later experiments. A sample volume of 20µL 
was used for all reactions and contained 10µL of 2x ddPCR supermix for probes 
(BioRad), primers, probes and template DNA. Primers were each used at a final 
concentration of 750nM and probes were each used at a final concentration of 250nM. 
The 20µL PCR reaction mix was loaded into the Bio-Rad QX-100 cartridge with 70µL of 
oil and droplets were formed following the manufacturer's instructions. The droplets were 
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carefully transferred to a 96 well plate and sealed for 5 sec using the PX1 PCR Plate 
Sealer (BioRad). The plate was immediately transferred to the thermocycler and run.  
PCR conditions 
PCR primers and probe sequences are shown in detail in Table 3.2. The 
fluorophores and quenchers used for each of the probes are also described. Cycling 
conditions were as follows: 10 minutes at 95°C, 45 cycles each consisting of a 30 second 
denaturation at 94°C followed by a 59°C extension for 60 seconds, and a final 10 minutes 
at 98°C. The ramp rate of the thermocycler was adjusted to 2°C/second. After cycling 
droplets were analyzed immediately.  
Standard curve and plasmid controls  
Plasmid concentration was estimated from the A260/A280 absorptivity ratio using 
a NanoDrop 2000 spectrophotometer (Thermo Scientific) and copy number was 
calculated using the size of the plasmid and a DNA copy number calculator, 
http://cels.uri.edu/gsc/cndna.html. A 5’ deletion plasmid containing the proviral sequence 
CP03P22E11, which contains a 5’ deletion removing the packaging signal, gag gene and 
the first part of pol (Bruner et al., 2016) was used as a negative control for the packaging 
signal primer/probe set. The 4F11 plasmid containing a 3’ deletion removing the env 
gene (Ho et al., 2013a) was used as a negative control for the env primer/probe set. The 
19CB3 plasmid containing a full-length patient derived hypermutated sequence (Ho et 
al., 2013a) was used as a negative control for the hypermutation discriminating probes. 





Samples were analyzed using the BioRad QuantaLife software v.1.0.596 using the 
probe mix triplex assay feature. A positive control HIV-1 cell line was used for gating 
each population. The software automatically calculates a concentration per µL of reaction 
mixture as well as a copy number per 20µL well. The total copy number per 20µL well 
values were reported from the software for all populations, packaging signal+ only, env+ 
only, and packaging signal+ and env+ double positive. The percent intact from ddPCR 
was calculated by taking the number of double positive copies/well and dividing by the 
total number of positive droplets/well (double positive divided by double positive plus 
both single positive populations). GraphPad Prism software was used to perform all 
statistical tests and correlation plots. When Pearson correlations were performed, P < 





3.5 Tables: Chapter 3 
Table 3.1 Only 5% of patient-derived hypermutated proviruses are predicted to be 
















CCTTAGGTTCTTAGGA 36% ✕	 ✓	 ✕	
CCTTAAGTTCTTAAGA 23% ✕	 ✕	 ✕	
CCTTAGGTTCTTAAGA 13% ✕	 ✓	 ✕	
CCTTAAGTTCTTAGGA 11% ✕	 ✓	 ✕	
CCTTGGGTTCTTGGGA 3% ✓	 ✕	 ✓	
CCTTGGGTTCTTAGGA 1% ✓	 ✓	 ✓	
CCTTAGGTTCTTAGAA 2% ✕	 ?	 ✕	
CCTTAGGTTCTTGAAA 2% ✕	 ?	 ✕	
CCTTAGGTTCTTGAGA 
 
2% ✕	 ?	 ✕	
CCTTAAGTTCTTAAAA 1% ✕	 ?	 ✕	
CCTTAAGTTCTTAGAA 1% ✕	 ?	 ✕	
CCTTGAGTTCTTAGGA 1% ✕	 ?	 ✕	
CCTTAGGTTCTTGGGA 1% ✓	 ✓	 ✓	
 
* APOBEC3G consensus sites in HXB2 are underlined. 
✕ - Did not fluoresce in qPCR/ddPCR 
✕ - predicted not to fluoresce based on tested hypermutation variants. 
✓- produced a fluorescent signal in qPCR/ddPCR 
✓- predicted to fluoresce based on tested hypermutation variants. 
? - fluorescent signal could not be predicted. 
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Table 3.2 IPDA Primers and Probes 
 
*Reverse compliment 













Psi_R 797-775*  GCACCCATCTCTCTCCTTCTAGC 
 
Psi Probe 758-740* FAM, MGB TTTTGGCGTACTCACCAGT 
 
Env_F 7736-7759  AGTGGTGCAGAGAGAAAAAAGA
GC 
Env_R 7851-7832*  GTCTGGCCTGTACCGTCAGC 
 
Env_intact 7781-7796 VIC, MGB CCTTGGGTTCTTGGGA 
 






















RPP30  GATTTGGACCTGCGAGCG 
RPP30-872-Ra 
 




RPP30 VIC, MGB CTGACCTGAAGGCTCT 
	 74	
3.6 Figures: Chapter 3 
Figure 3.1 Two amplicons performed in duplex are required to distinguish intact 














0 2,000 4,000 6,000 8,000 10,000


































2000 4000 6000 8000




















0.20 0.40 0.60 0.80 1.00
Fraction of deleted sequences correctly identified as defective
	 75	
(a) Sliding window analysis of theoretical single region PCR amplicons across the HIV 
genome using 260 full genome sequences from 22 individuals from previously published 
cohorts (Bruner et al., 2016; Imamichi et al., 2016).  Sequences that contained unmapped 
deletions from the Bruner et al. cohort were excluded from this analysis. Analysis was 
performed with 100bp increments. The start site of the theoretical amplicons are shown in 
HXB2 coordinates (x axis) and the proportion of proviruses detected by each amplicon 
that are actually intact is shown (y axis). (b) Sliding window analysis of potential primer 
locations for a two amplicon, duplex ddPCR assay using 258 full genome sequences from 
22 individuals that contained deletions from previously published cohorts (Bruner et al., 
2016; Imamichi et al., 2016). Amplicons selected for the ddPCR assay are shown by 





Figure 3.2 Hypermutation discriminating probes in the RRE of env should correctly 
identify 95% of hypermutated sequences as defective.  
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(a) Schematic of hypermutation discriminating probes in a hypothetical region of the 
HIV-1 genome (actual sequence not shown). The intact probe is designed over two 
APOBEC3G consensus sites (dashed boxes) and directly compliments the 
nonhypermutated or intact sequence, TGG. The probe will bind and fluoresce when 
bound to the intact sequence (top left) but will not bind to a hypermutated sequence due 
to multiple mismatches between the probe and sequence (bottom left). The hypermutated 
probe is designed over the same two APOBEC3G consensus sites but is designed to 
match the hypermutated sequence, TAA (top right). The probe will only fluoresce when 
it binds to a hypermutated sequence and not an intact sequence (bottom right). The 
hypermutated probe is labeled with a NED fluorophore which is detectable by qPCR but 
not by the ddPCR. Only the intact probe will produce detectable fluorescence in the 
IPDA ddPCR. (b) Analysis of APOBEC3F and 3G hypermutation in HIV-1 infected 
individuals. Sequences from existing cohorts (Bruner et al., 2016; Imamichi et al., 2016) 
were analyzed for APOBEC3F or 3G signatures using the using the full-length sequence 
for each clone and the Los Alamos hypermut algorithm (Rose and Korber, 2000). (c) 
Analysis of APOBEC3G consensus sites in the RRE of the HIV-1 env gene. Each point 
represents a single APOBEC3G consensus site in the HXB2 reference genome. Three 
regions (shaded boxes) were identified as having two APOBEC3G sites within the length 
of a standard hydrolysis probe. One region was excluded for use an IPDA amplicon due 
to low levels of APOBEC3G at a single site (purple box) and another was excluded 
because the G/C content of the region was too high for proper probe design (green). The 
selected region for an IPDA amplicon (blue box) is hypermutated in 95% of 
hypermutated sequences.  
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Figure 3.3 Schematic of IPDA workflow and analysis. 
	
The IDPA workflow begins with a blood draw of ~30mL from an HIV-1 positive 
individual. Resting cells are purified from whole blood and DNA is extracted and put into 
the droplet generator of the BioRad QX100 instrument. The sample is partitioned into 
20,000 nanoliter droplets which contain the primers and probes for an HIV-1 duplex PCR 
reaction. The droplets are cycled and then read by the droplet reader as positive or 
negative for one or both fluorophores. Droplets that are positive for both amplicons are 
considered to contain an intact provirus.  
	  
Extract DNA from 
resting CD4+ T Cells
Droplet Formation
PCRDetection and Analysis






Figure 3.4 Proposed assay readout for a duplex droplet digital PCR targeting the 
packaging signal and env regions of the HIV-1 genome.  
 
Assay schematic for droplet digital PCR with two amplicons, one in the packaging signal 
and one in the RRE of the HIV-1 genome. Each amplicon has a probe labeled with a 
unique fluorophore. The packaging signal amplicon, labeled with fluorophore 2 will 
detect any proviruses that have a genetically intact packaging signal, including 
hypermutated proviruses. The env amplicon incorporates two probes that can distinguish 
between hypermutated and non hypermutated (intact) sequence. The probe that binds to 
hypermutated sequences is unlabeled and the intact probe is labeled (fluorophore 1). Only 
proviruses that are not hypermutated and not deleted in the region of the probe binding 
will cause the intact probe to fluoresce. Proviruses that are positive for both fluorophore 1 
and 2 are identified as intact proviruses by the assay.  
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(a) Predicted amount of DNA shearing that will occur between two amplicons spaced 
7,159 bp apart, the distance between the packaging signal and env amplicons. The 
amount of DNA shearing between amplicons is dependent on the average size of the 
genomic DNA fragments from a given DNA extraction method (x axis). Extractions 
producing large gDNA fragments will have less DNA shearing and ones with small 
gDNA fragments will have a lower percentage of unsheared proviruses. (b) Schematic of 
the two HIV-1 amplicon locations and the distance between them. The RPP30 control set 
of two amplicons is shown relative to the 11 exons of RPP30 (black rectangles) and 
introns (blue line). The distance between the RPP30 amplicons mimics the distance 
between the packaging signal and env amplicons. (c) Levels of DNA fragmentation with 
the QIAamp DNA extraction kit is reproducible. DNA was extracted from 9 different 
samples from 4 donors and was subjected to a duplex RPP30 reaction (shown in b). The 
percent of genomes that were not fragmented was calculated by taking the total number 
of double positive droplets and dividing by sum of the double positive droplets plus the 
average of the single positive droplet populations. Each extraction was run in 2-3 
replicates on the BioRad QX100 instrument. The mean and standard deviation for each 
DNA extraction are shown.   
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Figure 3.6 Plasmids controls show specificity of the IPDA reaction.  
	
(a) The plasmid containing the proviral sequence CP03P22E11 which contains a 5’ 
deletion removing the packaging signal, gag gene and the first part of pol (Bruner et al., 
2016). The plasmid is single positive for the env amplicon (y axis). (b) The 4F11 plasmid 
containing a 3’ deletion of the env gene (Ho et al., 2013a). The plasmid is only positive 
for the 5’amplicon. In the IPDA this can be a gag (shown here) or packaging signal 




hypermutated sequence (Ho et al., 2013a). The plasmid is single positive for the gag or 
packaging signal amplicon (x axis). The plasmid is hypermutated in the env amplicon so 
the intact hypermutation discriminating probe does not bind. (d) NL4-3 full length 
plasmid, double positive for both amplicons. 5% of the droplets are not double positive, 
likely due to small amounts of shearing of the genome or plasmid degradation. All 
experiments were performed on the Raindance droplet digital PCR platform.  
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(a) Mixtures of 1,000 copies of a 5’ deletion plasmid, 3’ deletion plasmid and intact 
plasmid. A 1:1:1 ratio was observed between the three plasmids. See Fig. 3.6 for 
additional info on the origin of each plasmid. (b) Mixture of 1,000 copies each of a 5’ 
deletion plasmid and 3’ deletion plasmid and 100 copies of an intact plasmid. A 10:10:1 
ratio was observed as expected. (c) Mixture of 1,000 copies each of a 5’ deletion plasmid 
and 3’ deletion plasmid and 10 copies of an intact plasmid. A 100:100:1 ratio was 
observed as expected. All experiments were performed on the BioRad QX100 droplet 




Figure 3.8 Dilution series of HIV-1 controls shows the linearity, specificity and 
reproducibility of the IPDA ddPCR.  
	
(a) Standard curve dilution series of NL4-3 plasmid, with (light blue) or without (dark 
blue) added gDNA from PBMCs or (b) an HIV-1 cell line (5b5) with (purple) or without 
(green) added gDNA. The HIV-1 cell line, 5b5, was created by infecting Jurkat cells with 
a single-round GFP virus and sorting for GFP+ cells. The cell line was further 
characterized to verify it contained the correct HIV-1 sequence and only one HIV-1 
provirus per cell. Each dilution for each condition was performed in triplicate. The 
average and standard deviation for each dilution are plotted. All experiments were 
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Figure 3.9 Preliminary HIV-1 infected individual IPDA readouts correlate with full 
genome sequencing results.  
 
 
(a) Preliminary IPDA quantification of intact and defective proviruses from 14 HIV-1+ 
donors on ART. The percentage for each population of provirus was determined by 
dividing the number of droplets positive for that population by the total number of 
droplets positive for at least one fluorophore. Double positive droplets were defined as 
intact. Droplets positive for only the env amplicon were defined as 5’ defective 
proviruses and droplets positive for only the packaging signal amplicon were defined as 
3’ defective proviruses. (b) Pearson correlation of IPDA results with previously obtained 
full-genome sequencing results from 8 HIV-1 infected individuals (Bruner et al., 2016).  
Six individuals initiated treatment during the chronic phase of infection and two during 













































































Figure 3.10 IPDA detects primarily intact proviruses whereas single region PCRs 
detect predominately defective proviruses in chronically treated HIV-1 infected 
individuals.   
 
Sliding window analysis of a theoretical single region PCR at different locations in the 
HIV-1 genome (blue trace). The start site of the theoretical amplicons are shown in 
HXB2 coordinates (x axis) and the proportion of proviruses detected by each amplicon 
that are actually intact is shown (y axis). Sliding window analysis of a theoretical two 
region PCR assay with the first amplicon being the packaging signal (yellow trace). Only 
proviruses that are positive in both amplicons are detected as intact. Hypermutated 
sequences were considered not to be detected by the two region assay due to the 
incorporation of hypermutation discriminating probes as described in Fig. 3.2 and Table 
3.1. Analysis for both traces was performed on individuals from previously published 
cohorts initiating treatment during the chronic phase of infection (Bruner et al., 2016; 
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